





The long term effect of maternal gestational 




Dr Tam, Wing Hung 




Department of Obstetrics and Gynaecology 
Faculty of Medicine 




A Thesis submitted for the degree of Doctor of Medicine 









PRÉCIS ………………………………………………………….………… iii 
DECLARATION OF THE CANDIDATE’S ROLE ……………….……... xii 
STATEMENT OF WORK ………………………………………….…….. xiii 
DEDICATION AND ACKNOWLEDGEMENTS ………………….…..... xiv 
PUBLICATIONS ………………………………………………….……… xv 
PRESENTATIONS ……………………………………………….……..... xvi 







Obesity, type 2 diabetes mellitus (DM) and metabolic syndrome (MetS) are major 
public health challenges worldwide. The World Health Organization (WHO) 
predicts that globally the number of people with DM will increase from 171 million 
in 2005 to 366 million in 2030, with the majority of new patients coming from Asia 
and Africa. Owing to the silent nature of diabetes, diagnosis is often delayed with 
many patients presenting complications such as myocardial infarction. Although 
screening for DM may allow early detection and intervention, the 
cost-effectiveness and psychological impact of screening program remain 
controversial. 
 
On the basis of modelling, screening of non-Caucasians and young subjects with 
risk factors is considered cost effective due to high detection rates and potentially 
long disease duration faced by these subjects. In a retrospective analysis, 23% of 
Chinese women with a history of gestational diabetes had impaired glucose 
tolerance (IGT) and 13% had DM at 6 weeks postpartum. These women also had 
higher frequencies of other cardiovascular risk factors such as hypertension, 
obesity and dyslipidaemia than their age-matched healthy counterparts. 
 
There has been so far no prospective study a mother’s progression from gestational 
diabetes to type 2 DM and other cardiometabolic risks among the Chinese 
population.  Furthermore, recent data also suggested a rapid increase in the 





been well known that the ‘fetal programming’ hypothesis suggests that in-utero 
programming during fetal growth restriction increases the risks of insulin resistance, 
type 2 DM, hypertension and coronary heart disease in adulthood, studies also 
suggest maternal gestational diabetes increases the DM susceptibility of the 
offspring. However, the latter are limited by their retrospective study design and 
the absence of a control group for comparison. 
 
Between 1992 and 1994, a cohort of 1031 women were recruited consecutively into 
a study which aimed to define the optimal screening method and diagnostic criteria 
for gestational diabetes in Chinese at the Prince of Wales Hospital, a regional 
hospital with 8000 deliveries per annum at that time.  Subjects were classified into 
normal glucose tolerance or gestational diabetes on the basis of their 75 gram oral 
glucose tolerance test results at the index pregnancy.  All 134 women with 
gestational diabetes and a random cohort of age-matched 268 normal controls were 
selected by a computer programme from the original cohort; a prospective follow 
up study was conducted on the mothers and their children offspring of the index 
pregnancy for clinical assessments after a median 8 and 15 years post-delivery. The 
main objective is to investigate the effect of maternal gestational diabetes on both 





These issues are examined in the work leading to this thesis. These can be 
translated formally into the following hypotheses to be tested. 
 
Hypothesis 1: 
That Chinese women with a prior history of gestational diabetes had 
increased cardiometabolic risk 
 
A total of 203 women [67 with gestational diabetes during the index 
pregnancy and 136 normal controls] completed a follow up assessment at 8 
years post-delivery; the conversion rate to abnormal glucose tolerance 
(AGT) and DM were 25.1% and 4.4% respectively. At 15 years, 139 
women (45 with gestational diabetes during pregnancy and 94 normal 
controls) completed the assessment; 30.2% progressed into AGT among 
which 13% were type 2 DM. 
 
Type 2 DM increased from 9% (n = 6/67) to 24.4% (n = 11/45; 2.7-fold 
increase) and from 2.2% to 5.3% (2.4-fold increase) among the women with 
gestational diabetes and normal glucose tolerance (NGT) during pregnancy. 
At 8 years post-delivery, women with a prior history of gestational diabetes 
had a significantly higher rate of hypertension and a more adverse lipid 







At 15 years post-delivery, women with a prior history of gestational 
diabetes had significantly higher prevalence of hypertension (35.6% vs. 
16.0%), type 2 DM (24.4% vs. 5.3%) and impaired glucose regulation (IGR) 
(26.6% vs. 14.9%), as well as a higher plasma triglyceride level (1.33 ± 
0.80 mmol/L vs. 1.06 ± 0.57 mmol/L; p = 0.003) than women with NGT. 
 
In a multivariate model, history of gestational diabetes at index pregnancy 
increased the odds (95% CI) of future progression to AGT, DM and 
hypertension at 15 years post-delivery by 5.2 (2.2 - 12.1), 8.0 (2.2 - 28.3) 
and 3.3 (1.4 - 7.8) respectively. After adjustment for the conversion to type 
2 DM, maternal gestational diabetic status was still predictive of women’s 
hypertension at 15 years post-delivery [odds ratio (95% CI): 2.5 (1.0 - 6.2)]. 
 
Conclusion 1: 
The results of the study supported Hypothesis 1.  Chinese women with a 
prior history of gestational diabetes had increased risk in progression to 
AGT, DM and hypertension. 
 
Hypothesis 2: 
That glycaemic indices measured at mid-gestation of the index 







Receiver Operator Characteristic (ROC) analysis was performed to assess 
the prediction of women’s cardiometabolic risk, namely AGT, DM, 
hypertension and MetS at 8 and 15 years post-delivery, by the glycaemic 
variables [50 gram glucose challenge test (GCT), fasting and second hour 
plasma glucose (FPG & 2-h PG) at a 75 gram oral glucose tolerance test 
(OGTT)] measured at mid-gestation of the index pregnancy. 
 
All glycaemic indices were predictive of AGT and DM at both 8 and 15 
years after the index pregnancy while only FPG and 2-h PG were predictive 
of hypertension.  The prediction of MetS was confined to FPG at 15 years 
post-delivery only.  GCT showed a good prediction on mothers’ future risk 
in DM at both 8 year and 15 years (area under the ROC curves = 0.81 and 
0.84 respectively).  
 
In mothers’ who had a GCT ≥ 7.7 mmol/L at mid-gestation of the index 
pregnancy, the relative risks of conversion to type 2 DM were 15 and 14 at 
8 and 15 years post-delivery respectively.  Likewise, in those with a 2-h 
PG at OGTT ≥ 7.2 mmol/L, the relative risks were 5.3 and 4.9 at 8 and 15 
years respectively.  Both cut-off levels are lower than the current criteria 
for a positive test. 
 
Conclusion 2: 
The results in this study supported Hypothesis 2.  Glycaemic indices, in 





women’s future cardiometabolic risk.  The optimal threshold of GCT and 
glycaemic levels at the OGTT in predicting women’s future 




That maternal gestational diabetes increases the offspring’s 
cardiometabolic risk. 
 
A total of 164 children (63 of mothers with gestational diabetes and 101 of 
mothers with NGT during pregnancy) of the mother cohort had completed a 
follow up assessment at a median age of 8 years while amongst them 129 
children (42 of mothers with gestational diabetes and 87 of mothers with 
NGT during pregnancy) also completed a second follow up assessment at 
15 years of age.  There was no significant difference in AGT between the 
offspring of mothers with gestational diabetes and those of normal controls 
at both 8 and 15 years of age. 
 
At 8 years of age, children offspring of mothers with gestational diabetes 
were found to have significantly higher systolic (94 ± 1.2 mmHg vs. 88 ± 
0.9 mmHg; p <0.001) and diastolic blood pressure (62 ± 0.8 mmHg vs. 57 
± 0.6 mmHg; p <0.001), and lower HDL-C level (1.58 ± 0.04 mmol/L vs. 
1.71 ± 0.03 mmol/L; p = 0.019) than children of NGT mothers. The 






The results in this study supported Hypothesis 3. Maternal gestational 
diabetes increases the offspring’s cardiometabolic risk in early childhood, 
namely higher risk of hypertension and adverse lipid profile. 
 
Hypothesis 4: 
That in utero hyperinsulinaemia in maternal gestational diabetes 
increases the offspring’s cardiometabolic risk 
 
A high umbilical cord blood insulin level (≥90th percentile based on that of 
the original cohort) was found to be an independent risk factor for AGT at a 
median 8 years of age (odds ratio: 8.9; 95% CI: 1.08-72.7).  A high 
umbilical cord blood C-peptide level (≥90th percentile) was also predictive 
of adolescent MetS at 15 years of age (odds ratio: 17.6; 95% CI: 1.32–235), 
after adjustment for birth weight, Tanner staging, maternal gestational 
diabetic status and maternal BMI at follow up evaluation.  Both cord blood 
insulin and C-peptide levels ≥90th percentile were also independent 
predictors of adolescents’ overweight (as defined by BMI ≥90th age- and 
gender-specific specific percentile) at 15 years of age. 
 
Conclusion 4: 
The results in this study supported Hypothesis 4.  In utero 





independent predictor of adolescent MetS and adolescent overweight at 15 







In this 15 year follow up study in a Chinese population, we confirmed that maternal 
gestational diabetic status significantly increased women’s future cardiometabolic 
risk. Glycaemic levels below the current criteria for a positive screening test for 
gestational diabetes and for the diagnosis of gestational diabetes still significantly 
predict women’s future risk. In utero hyperinsulinaemia, which caused by an 
intrauterine hyperglycaemic environment, was found to predict children’s AGT and 
adolescents’ overweight and MetS. The results had important implication that the 
current diagnostic criteria for gestational diabetes may not be discriminative in 
predicting both the mothers and their children’s future cardiometabolic risk. 
Although recent research has re-visited and emphasised on the diagnostic criteria of 
gestational diabetes which best predicted adverse pregnancy outcome, future study 
should also scrutinise on the optimal glycaemic threshold, either in screening or 
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GESTATIONAL DIABETES & FUTURE CARDIOMETABOLIC RISK – AN OVERVIEW 
 
1.1 Historical background 
 
Gestational diabetes mellitus (GDM) is defined as carbohydrate intolerance of any 
degree with onset or first recognition during pregnancy, regardless of whether the 
patient requires insulin or not (American Diabetic Association 2006).  The concept 
dates back to the 50 years ago when the condition was first known as “potential 
diabetic” or “pre-diabetic” which denoted a “preclinical phase of diabetes” shown 
up at the time of pregnancy (Wilkerson 1959a; Wilkerson 1959b).  
 
The first diagnostic criteria of GDM was established on the basis of a 3-hour 100 
gram oral glucose tolerance test (OGTT) in which the threshold was arbitrarily 
defined at 2 standard deviations (SD) above the mean plasma glucose concentration 
at each hour from a sample of 752 pregnant women (Wilkerson and O'Sullivan 
1963).  The derived criteria was then applied to another cohort of 1013 women to 
predict their long term risk of diabetes mellitus (DM) at 5-10 years post-delivery 
(O’Sullivan & Mahan 1964).  It confirmed the association between GDM based on 
the diagnostic criteria and the women’s long term DM risk (O’Sullivan & Mahan 
1964).  The O'Sullivan and Mahan’s criterion was further modified as blood 
glucose determination was changed from the use of whole blood to venous plasma 
samples.  The National Diabetes Data Group (NDDG) criteria has mostly been 
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adopted while some others used a cutoff at lower glycaemic values, the Carpenter 
and Coustan criteria (Carpenter & Coustan 1982). 
 
On the basis of a 75 gram oral glucose tolerance test (OGTT), World Health 
Organization (WHO) applied the same diagnostic criteria for non-pregnant to 
pregnancy to diagnose impaired glucose tolerance (IGT) [i.e. fasting plasma 
glucose level (FPG) <7.0 mmol/L and 2-hour plasma glucose level (2-h PG) ≥7.8–
11.1 mmol/L)] and GDM (FPG ≥7.0 mmol/L and/or 2-h PG ≥11.1 mmol/L).  Since 
1999, WHO recommended to use the term “Gestational diabetes” to include both 
IGT and GDM in pregnancy.  
 
Nonetheless, neither the criteria modified from O’Sullivan and Mahan nor the 
WHO criteria was based specifically on the perinatal outcomes. Until recently, the 
“Hyperglycaemia and adverse pregnancy outcome (HAPO) study” result had 
demonstrated that a graded association existed between less severe degree of 
maternal hyperglycaemia below the current standard diagnostic criteria and a 
number of adverse pregnancy outcomes, namely, primary caesarean section, birth-
weight >90th percentile, and cord C-peptide > 90th percentile (HAPO Study 
Cooperative Research Group 2008).  Recently, a new diagnostic criteria was 
proposed by the International Association of Diabetes and Pregnancy Study Groups 
Consensus Panel (IADPSG 2010) on the basis of the HAPO study result.  A 















(mmol/L) Diagnostic criteria 
NDDG, 1979  100  5.8  10.6  9.2  8.1 Either 2 = GDMEither 1 = Borderline
Carpenter & Coustan, 1982 
ACOG, 2001 100  5.3  10.0  8.6  7.8 
Either 2 = GDM
Either 1 = Borderline
WHO, 1999 75  7.0 
< 7.0
-  11.1  7.8–<11.0 - 
Either 1 = GDM
Either 1 = IGT
RANZCOG, 2004 75  5.5 -  8.0 (Aus)  9.0 (NZ) - Either 1 = GDM 
JDA, 2002 75  5.6  10.0  8.3 - Either 2 = GDM 
CDA, 2008 75  5.3  10.6  8.9 - Either 2 = GDMEither 1 = IGT
IADPSG, 2010 75  5.1  10.0  8.5 - Either 1 = GDM 
 
ADA, American Diabetic Association; ACOG, American College of Obstetricians & Gynecologists; ADIPS, The Australasian Diabetes in Pregnancy Society; Aus, 
Australia; CDA, Canadian Diabetes Association; IADPSG, International Association of Diabetes and Pregnancy Study Groups; JDA, Japan Diabetes Association; 
NDDG, National diabetes data group NZ, New Zealand; RANZCOG, Royal Australian & New Zealand College of Obstetrics and Gynaecology; WHO, World Health 
Organization 
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Since all the studies related to the thesis were completed before the new IADPSG 
diagnostic criteria, we had chosen the WHO (1999) criteria and standardised the 
term “gestational diabetes” to define carbohydrate intolerance described in the 
thesis. 
 
1.2 Pregnancy physiology vs. gestational diabetes 
 
Pregnancy is a natural state of insulin resistance (Catalano et al. 1991; Catalano et 
al. 1999), mediated through maternal cortisol and placenta-derived hormones such 
as human placental lactogen, progestogen and oestrogen (Creasy et al. 2009).  
Throughout the last few decades, there has been debate whether hyperglycaemia is 
merely a normal physiological state of pregnancy rather than a real disease entity 
(Beard & Hoet 1982; Jarrett 1993).  Until recently, it was confirmed by the results 
of two randomised controlled trials that treatment to mild GDM achieved primarily 
by diet and lifestyle modification, reduced the frequency of large-for-gestational 
age at birth and preeclampsia (Crowther et al. 2005; Landon et al. 2009). 
 
The clinical manifestation of hyperglycaemia in gestational diabetes is likely 
resulted from a combination of insulin resistance and inadequate beta cell function 
(Buchanan et al. 1990; Kautzky-Willer et al. 1997).  A number of epidemiological 
risk factors associated with insulin resistant and reduced beta cell function (e.g. 
obesity, family history of diabetes, advanced age) are also predictors of gestational 
diabetes (Buchanan et al. 1990; Kautzky-Willer et al. 1997).  In other words, the 
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manifestation of gestational diabetes at the period of insulin resistance during 
pregnancy can uncover a woman’s potential risk of future DM. 
 
1.3 Diabetes mellitus – a global epidemic 
 
Type 2 DM is a major public health challenges worldwide. Its prevalence is 
estimated to be 4.4% by 2030 with the total population affected being 366 million; 
majority of new patients being from Asia and Africa (Wild et al. 2004).  Despite its 
prevalence being similar between men and women for most age groups, it is more 
prevalent in women after the age of 65 years (Wild et al. 2004).  DM is estimated 
to have accounted for 3 million deaths globally in 2000. Again, DM was 
responsible for a higher proportion of deaths amongst women than men in all age 
groups at all regions (Roglic et al. 2005).  In the South East Asia, at least 1 in 5 
deaths amongst women at the 35-64 years age group are due to DM (Roglic et al. 
2005). 
 
Owing to the silent nature of DM, diagnosis is often delayed until complications 
such as myocardial infarction (Norhammar et al. 2002; Bartnik et al. 2004).  From 
large epidemiology studies, DM is a much stronger risk factor for coronary heart 
disease (CHD) mortality in women than in men (Hu et al. 2001; Becker et al. 2003; 
Juutilainen et al. 2005). It has been reported that the risk of CHD mortality was 
50% higher in women than in men with DM (Huxley et al. 2006).  Despite a 
decline in the overall DM related death in the recent 30 years, the mortality rates of 
women with DM remained static and the risk of death was more than doubled in 
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women with DM than those without (Gregg et al. 2007).  From a women’s health 
perspective, it may be cost-effective to identify women at high risk of developing 
DM and intervene early with lifestyle modification followed by pharmacological 
treatment if necessary. 
 
1.4 History of gestational diabetes & progression to Type 2 DM 
 
There is now much evidence to support that a past history of gestational diabetes is 
a strong risk factor for DM.  In a systematic review of 28 studies, the cumulative 
incidence of type 2 DM in women with prior history of gestational diabetes ranged 
from 2.6% at 6 weeks to 70% at 28 years post-delivery (Kim et al. 2002).  Recent 
meta-analyses of controlled studies also demonstrated that gestational diabetes 
conferred a 6 to 7.5-fold increased risk of DM while 10–30% of women with DM 
also had a prior history of gestational diabetes (Cheung & Byth 2003; Bellamy et al. 
2009).  However, the conversion rate to DM with the length of follow up appeared 
conflicting in the literature.  Kim and colleagues (2002) showed that the 
progression to type 2 DM increased steeply in the first 5 years after delivery and 
conversion rate plateau afterwards.  In contrast, Bellamy and colleagues (2009) 
showed that the relative risk of DM increased from 4.7 within 5 years to 9.3 at 
more than 5 years from a pregnancy complicated by gestational diabetes.  Although 
the latter study did not demonstrate any heterogeneity in the subgroup analysis, 
they do suspect a possibility of variation among different ethnic groups. 
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In a prospective study of 800 Chinese women with gestational diabetes during 
pregnancy, 23% and 13% were found to have impaired glucose tolerance (IGT) and 
DM respectively at 6 weeks postpartum (Ko et al. 1999a).  However, there had not 
been any long term prospective study on the progression to Type 2 DM, as well as 
other cardiometabolic risk, in Chinese women with history of gestational diabetes. 
 
1.5 History of gestational diabetes & cardiometabolic risk 
 
Cardiometabolic risk, also known as metabolic syndrome (MetS) or insulin 
resistance syndrome, comprises obesity (particularly central or abdominal obesity), 
dyslipidaemia, elevated blood pressure and elevated plasma glucose, is associated 
with 2 to 3 fold increased risk of DM and premature cardiovascular disease (Ford 
2005).  Despite some overlaps between DM and MetS (Eckel et al. 2005), the 
differential risk associations between gestational diabetes and these high risk 
conditions remain to be clarified.  While Lauenborg and colleagues (2005) have 
shown that a history of gestational diabetes confers a 3-fold increased risk of MetS, 
Albareda and colleagues (2005) showed risk association with only some 
components of the MetS.  In the local study described in the previous session, 
women with gestational diabetes also had higher frequencies of other 
cardiovascular risk factors such as hypertension, obesity and dyslipidaemia than 
their age-matched controls without gestational diabetes (Ko et al. 1999a).  Despite 
the high prevalence of DM in young Chinese (Gu et al. 2003), there is a paucity of 
prospective data on the risks of impaired glucose regulation (IGR), DM or MetS in 
Chinese women with history of gestational diabetes. 
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1.6 Type 2 DM among children and adolescents 
 
The incidence of type 2 DM has rapidly increased among children and adolescents 
worldwide (Rosenbloom et al. 1999; Kaufman 2005).  It represents up to 45% of 
all new cases of childhood DM in the United States (Silverstein & Rosenbloom 
2001).  Moreover, the prevalence has increased by 3-fold among adolescents in 
North America (Fagot-Campagna et al. 2001; Duncan 2006), rising up to 5.4/1000 
in certain ethnic population in the last decade (Acton et al. 2002).  Among Japanese 
children, a 30-fold increase in the incidence of type 2 DM was observed over two 
decades (Rosenbloom et al. 1999).  The incidence of type 2 DM among Japanese 
high school students was also increased by 6-fold over the periods from 1974-1980 
to 1991-1995 (Kitagawa et al. 1998; Urakami et al. 2005). While it is established 
that the prevalence of type 2 DM in adults parallels the increasing rate of obesity 
and adiposity, strong association between obesity and type 2 DM in the youth is 
also evident (EURODIAB ACE Study Group 2000). The US national longitudinal 
survey of youth has demonstrated that the prevalence of overweight increased 
annually from 1998 by 3.2% to 5.8% depending on the ethnicity, with African-
American and Hispanic children being fatter and heavier (Dwyer et al. 2000; 
Strauss & Pollack 2001); the prevalence of overweight among adolescents also 
increased significantly from 1999 to 2004 (Ogden et al. 2006).  A recent 
epidemiological study also highlighted increasing hypertension and hence 
cardiovascular risk in youth across different BMI percentiles (Sorof et al. 2004).  
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The prevalence of MetS in childhood and adolescence will continue to rise as this 
rate of obesity increases (Caprio et al. 1996; Caprio & Tamborlane 1999; Caprio 
2002; Cook et al. 2003). While the combination of unhealthy diet and genetic 
predispositions are recognised as the cause of this epidemic of type 2 DM, obesity 
and MetS in the young population, recent research has found a strong link with in-
utero programming and developmental origin.  
 
1.7 Type 2 DM among offspring of mothers with gestational diabetes 
 
There has been much epidemiological evidence that the relationship between the 
future DM risk and birth weight follows a U-shaped curve (Pettitt & Jovanovic 
2001); that means children born either small or large for gestational age would 
have an increased risk of DM.  On the other hand, in-utero exposure to a diabetic 
environment was also found to increase the DM risk to the offspring in both human 
and animal studies. 
 
In Pima Indians, offspring of mothers who had type 2 DM during pregnancy were 
at a higher risk of developing type 2 DM than those who developed it after the 
index pregnancy (Pettitt et al. 1988; Dabelea et al. 2000; Dabelea & Pettitt 2001).  
The prevalence of adolescent obesity was higher in offspring exposed in-utero to 
maternal DM as compared to offspring of non-diabetic mother (Pettitt et al. 1983). 
Furthermore, the association between nutritional excess during pregnancy and 
future MetS in the offspring was supported by animal models (Armitage et al. 2005; 
McMillen et al. 2005; Taylor & Poston 2007). 
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Although recent studies have demonstrated that dietary pattern being the most 
important contributing factor to obesity and insulin resistance in young adults 
(Pereira et al. 2002; Pereira et al. 2005), animal research has confirmed that in 
utero hyperinsulinaemia plays an important role in the programming on the 
hypothalamic neural network that regulates the appetite and eating behaviour, 
thereby influencing weight gain.  In animal experiment in which protamine zinc 
insulin was injected to rats on days 15-20 of gestation, Jones et al. (1995) 
demonstrate a significant obesity in the offspring beginning about 50 days of age.  
This obesity is accompanied by elevated medial hypothalamic extracellular 
norepinephrine levels.  At the same time, they also found a significant enhancement 
of dopamine-beta-hydroxylase immunoreactivity in fibers innervating the 
paraventricular nucleus of the hypothalamus in 121-day-old, gonadally intact male 
offspring of insulin-injected dams (Jones et al. 1996).  It was then proposed that the 
impact of maternal insulin injections on offspring obesity may be mediated through 
its organizing action on feeding-related fibers in the paraventricular nucleus. 
 
While study had suggested that maternal gestational diabetes increased DM 
susceptibility of the offspring, results were limited by small sample size and 
absence of a control group for comparison.  Plagemann et al. (1997) investigated 
on 69 infants of gestational diabetic mothers between 1 and 9 years of age and 




1.8 Cardiometabolic risk in children exposed to maternal gestational 
diabetes 
 
Childhood MetS is also much more common than previously reported; its 
prevalence is highest among obese children, ranging between 40 and 50% 
depending on the severity of obesity (Csabi et al. 2000; Eisenmann 2003; Cruz et al. 
2004; Weiss et al. 2004).  In the offspring of mothers with gestational diabetes, the 
risk of MetS in large for gestational age infants was found to be increased threefold 
at the age of 7 and fourfold at the age of 9, compared with children who were of 
appropriate size for gestational age at birth (Boney et al. 2005).  The study also 
observed that obesity at 11 years of age was a strong predictor of insulin resistance 
(Boney et al. 2005).  Although intrauterine exposure to hyperglycaemia from 
maternal DM is a known risk factor for type 2 DM developing in the offspring, its 
effect on childhood cardiometabolic risk factors, namely obesity, dyslipidaemia, 
insulin resistance and blood pressure, has not been studied systemically, especially 
in Chinese population. 
 
1.9 Long term follow up on mothers & children cohort 
 
In view of a paucity in literature on the long term effect of gestational diabetes on 
the mothers and their offspring in Chinese population, a series of prospective 
studies were performed to follow up both the mothers and their offspring from a 
cohort of women, who had been recruited into a previous study on gestational 
diabetes, in order to evaluate their cardiometabolic status at both 8 and 15 years 
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after the index pregnancy (Tam et al. 2007; Tam et al. 2008; Tam et al. 2010; Tam 
et al. 2011). 
 
In this thesis, four hypotheses were examined: 
1. That Chinese women with prior history of gestational diabetes had increased 
cardiometabolic risk 
2. That glycaemic indices measured at mid-gestation of the index pregnancy 
predict women’s future cardiometabolic risk 
3. That maternal gestational diabetes increases the offspring’s cardiometabolic risk
4. That in utero hyperinsulinaemia from maternal gestational diabetes increases 
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This chapter focuses on the research methodology in the follow up assessments on 





Between 1992 and 1994, a cohort of 1031 women were recruited consecutively into 
a study which aimed to define the optimal screening method and diagnostic criteria 
for gestational diabetes in Chinese women at the Prince of Wales Hospital, a 
regional hospital with 8000 deliveries per annum at that time.  In this original study, 
various diagnostic definitions were compared using the plasma glucose profiles as 
a reference in low risk Chinese population (Fung et al. 1996).  In the same study, 
the optimal cut-off threshold of various screening tests, namely spot glucose, 
fasting glucose and glucose challenge test (GCT), for gestational diabetes were also 
examined (Tam et al. 2000). 
 
Of these 1031 women, 942 had complete data collection during their index 
pregnancies and were eligible for reassessment in this study.  On the basis of their 
75 gram OGTT results at the index pregnancy, women were classified into normal 
glucose tolerance (NGT) (i.e. FPG <7.0 mmol/L and 2-h PG <7.8 mmol/L; n = 
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808), gestational impaired glucose tolerance (GIGT) (i.e. FPG <7.0 mmol/L and  2-
h PG 7.8-11.1 mmol/L; n = 127) and GDM (i.e. FPG 7.0 mmol/L and/or 2-h PG 
11.1 mmol/L; n = 7) according to the 1999 WHO criteria in which gestational 
diabetes included both GIGT and GDM.  The treatment criteria for GDM was on 
the basis of a 3-hour 50 gram OGTT results; subjects who had 2 or more abnormal 
glycemic levels were offered treatment.  A total of 36 (3.8%) women were treated 
with dietary therapy while 2 (0.2%) were supplemented with insulin. 
 
The study was a prospective case-control design (with index cases vs controls at 
1:2 ratio).  All 134 mother-child pairs of the gestational diabetes group and 268 
mother-child pairs of the normal glucose tolerance group, matched for maternal age, 
were invited for a follow up study at 8 and 15 years post-delivery for the 
development of DM and other metabolic risks such as hypertension, obesity and 
dyslipidaemia.  
 
Contact details including telephone numbers and addresses were retrieved from 
medical records supplemented by updated information from the outpatient 
computer registry.  All relevant medical information was obtained by review of 
case notes.  All the studies were approved by the Chinese University of Hong Kong 
Clinical Research Ethics Committee (details in session 2.8).  Written informed 




2.2 Obstetric and neonatal information 
 
The maternal characteristics of the study cohort, namely maternal age, parity, 
gestational age, body weight & weight at booking visit, family history of DM; and 
obstetric data such gestational age at birth, mode of delivery, birth weight, sex, 
Apgar score and neonatal outcome were all recorded. 
 
2.2.1 Maternal glycaemic indices at pregnancy 
 
In the original study, mothers who had no previous history of DM underwent a 
GCT (i.e. plasma glucose levels at 1-hour after a 50-gram glucose load given in a 
non-fast state) between 24 and 28 weeks and followed with a 75-gram oral 
glucose tolerance test (OGTT) at 2-4 weeks afterwards.  All the mothers in the 
cohort had an ultrasound scan examination at 20 weeks of gestation to confirm the 
gestational age and to assess the fetal morphology. 
 
2.2.2 Umbilical cord blood C-peptide & insulin levels 
 
Following delivery, the cord was clamped immediately and blood drawn for 
determination of C-peptide and insulin levels.  Radioimmunoassay of insulin and 
C-peptide was performed using reagent kits obtained from Novo-Nordisk A/S 
(Copenhagen, Denmark).  The detection limit of the insulin assay in 3 μU/ml and 
the inter-assay coefficient of variation is 6%. The detection limit of the C-peptide 
assay is 0.3 nmol/L, and both intra-assay and inter-assay coefficients of variation 
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were 11% (Roach 1998).  Figure 2.1 summarised the recruitment of mothers and 
children in the follow up study. 
 
2.2.3 Definition of antenatal variables 
 
Family history of DM was defined as DM occurred in any 1 of the mother’s first 
degree relative in the original study.  Advanced maternal age was defined as 
maternal age ≥ 35 years old at the expected date of delivery.  Although pre-
pregnancy weight should be a much better index to determine maternal obesity, this 
data was not available for most of the subjects.  Instead, maternal overweight at 
booking was classified as maternal BMI ≥ 23 kg/m2 to the Asian criteria (WHO 
2000). 
 
2.3 Follow up assessment of the mothers 
 
Obstetric history and medical history were documented through a structured 
questionnaire at the follow up assessment at both 8 and 15 years post-delivery.  
History of hypertension, DM, hyperlipidaemia and related medication were 
documented.  All other significant medical conditions were also recorded.  Body 
weight, height, hip and waist circumferences were measured in light clothing.  
Blood pressure (BP) was measured in the non-dominant arm with the Dinamap 
PRO-100 device (Critikon, Milwaukee, WI) thrice, 1 minute apart, and after at least 
5 minutes of rest.  The mean BP reading was used for analysis.   
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Venous blood was collected from the forearm for renal function test, liver function 
test, lipid profiles [total triglyceride (TG), total cholesterol (TC), high density 
lipoprotein cholesterol (HDL-C) & low density lipoprotein cholesterol (LDL-C)].  
All subjects underwent a 75-gram OGTT with 5 points plasma glucose and insulin 
levels at 0, 15, 30, 60 and 120 minutes after an overnight fast of at least 8 hours.  If 
the subjects had been diagnosed DM and received pharmacological treatment, 
fasting glucose and HbA1c were performed instead. 
 
Serum insulin was measured by DAKO insulin ELISA (DAKO Diagnostics, 
Denmark House, Ely, Cambridgeshire, UK).  Plasma lipid profiles were measured 
by enzymatic methods with DP Modular Analytics (Roche Diagnostics, 
Indianapolis, IN, USA) while PG was measured by the hexokinase method. 
 
At the 15 year follow up assessment, women underwent a repeated OGTT with 
plasma glucose levels at 0, 60 and 120 minutes after an overnight fast of at least 8 
hours.  If the subjects had been diagnosed DM and received pharmacological 
treatment, a fasting glucose was performed together with HbA1c instead.  Body 
weight, height, hip, waist circumferences and BP were measured as that in the 8-
year follow up.  The percentage of body fat was assessed using a body composition 
analyzer (Tanita Inc., Tokyo, Japan, Model TBF 410). Women with known 
diagnosis of hypertension on medication or the mean BP reading ≥ 140/90 mmHg 
based on the seventh report of Joint National Committee (Chobanian et al. 2003) 
were used to define hypertension. 
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Figure 2.1 Flow chart of mothers and children participating in the 8 and 15 year 




 Body height, weight, waist circumference, hip 
circumference & percentage of body fat  
 Blood pressure  
 OGTT (1.75 g/kg or 75 gram glucose load)  




































 Body height, weight, waist circumference, hip 
circumference & percentage of body fat  
 Blood pressure  
 75 gram OGTT (fasting glucose & HbA1c 
instead if known DM on medication) 
 Renal, liver function tests & lipid profile  
 50 gram GCT (at booking visit) 
 75 gram OGTT (24 - 28 weeks gestation) 
 Plasma glucose profile (within 2 weeks of OGTT while on normal diet) 
 Umbilical cord insulin & C peptide (at delivery) 
1031 women without history of DM












 Body height, weight, waist circumference, hip 
circumference & percentage of body fat  
 Blood pressure  
 75 gram OGTT + insulin levels (0, 15, 30, 60, 
120 minutes) [fasting glucose & HbA1c 
instead if known DM on medication] 
164 children: 
 Body height, weight, waist circumference, hip 
circumference & percentage of body fat  
 Blood pressure  
 OGTT (1.75 g/kg or 75 gram glucose load + 
insulin levels 0, 15, 30, 60, 120 minutes)  
 Renal, liver function tests & lipid profile  
402 mother-child pairs 
NGT (normal glucose tolerance), GIGT (gestational impaired glucose tolerance), GDM (gestational diabetes mellitus) were 
classified according to 1999 WHO criteria. 
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All subjects who were diagnosed with hypertension or DM at both follow up 
assessments were referred to outpatient clinic for further management.  Women 
diagnosed IGR were provided with health education and advised on diet and 
lifestyle modification as well as suggestion to seek regular medical follow up. 
 
2.4 Follow up assessment of the children and adolescents 
 
At the 8 year follow up assessment, children who themselves and their mothers 
consented to the study, had their venous blood collected from the forearm for renal 
function test, liver function test, lipid profiles [total triglyceride (TG), total 
cholesterol (TC), high density lipoprotein cholesterol (HDL-C) & low density 
lipoprotein cholesterol (LDL-C)]. They also underwent an OGTT after an 
overnight fast of at least 8 hours (at a glucose load 1.75 g/kg body weight but not 
exceeding 75 g).  Venous blood samples were obtained for plasma glucose and 
insulin assay before (0 minute) and 15, 30, 60, and 120 minutes after the glucose 
load. 
 
Children’s weight and height were measured to the nearest 0.1 kg using a SECA™ 
electronic scales (Hamburg, Germany), and to the nearest 0.1 cm using a 
statiometer in light clothing; their waist circumference was measured to the nearest 
0.5 cm using a non-elastic flexible tape at the mid-point between the lower ridge of 
the ribs and the top of the iliac crest, at minimal respiration. The percentage of 
body fat was assessed using a body composition analyzer (Tanita Inc., Tokyo, 
Japan, Model TBF 410). 
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BP was measured in each child’s non-dominant arm using a Dinamap PRO-100 
device (Critikon, Milwaukee, WI) with pediatric cuffs of appropriate bladder size 
which covered at least two-thirds of the arm circumference.  Measurements were 
also performed thrice, at 1-minute intervals, after ≥ 5 minutes of rest.  The mean 
BP reading was used for analysis.  
 
At 15 year follow up, adolescents consented to the study underwent an OGTT after 
an overnight fast of at least 8 hours (with 75 gram glucose load or at a glucose load 
1.75 g/kg body weight if the body weight < 42.8 kg). Venous blood samples were 
obtained for plasma glucose before (0 minute), 60 and 120 minutes after the 
glucose load.  
 
Body weight, height, waist & hip circumferences, and percentage of body fat were 
measured in light clothing as previously described.  Mean BP was recorded after 3 
consecutive measurements in the non-dominant arm using an automated vital signs 
monitor (Welch Allyn Inc., Oregon, United States, Model 53000) with appropriate 
cuff size.  The adolescents’ pubertal stage was assessed using a validated self-
assessment questionnaire with gender-specific line drawings and supplementary 




2.5 Definition of abnormal glucose tolerance and metabolic syndrome 
 
2.5.1 Definition of abnormal glucose tolerance (AGT) 
 
The latest American Diabetic Association (2006) diagnostic criteria was used to 
define glycaemic status at the time of the follow up assessment. 
1. DM was defined as a fasting plasma glucose level (FPG) 7.0 mmol/L or a second 
hour glucose level (2-h PG) 11.1 mmol/L; 
2. IGT was defined as a FPG <7.0 mmol/L and a 2-h PG 7.8 and <11.1 mmol/L; & 
3. Impaired fasting glucose (IFG) as a FPG 5.6 mmol/L and < 7.0 mmol/L. 
 
IFG and IGT were classified as IGR according to 1999 WHO recommendation.  
Abnormal glucose tolerance (AGT) was defined as IGR or DM. 
 
2.5.2. Definition of metabolic syndrome (MetS) in adult 
 
Several criteria had been proposed which included the WHO (1999), European 
Group for the Study of Insulin Resistance (Balkau & Charles 1999) and National 
Cholesterol Education Program - Third Adult Treatment Panel (Adult Treatment 
Panel III 2001) previously.  In 2005, the International Diabetes Federation (IDF) 
(Alberti et al. 2005) had proposed a new definition and was adopted in this thesis.  
Applying the Asian-specific definition of central obesity, we diagnosed MetS in 
adults as the subject met the first criteria plus any 2 other risk factors:  
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1. Central obesity: waist circumference (WC) 80 cm 
2. FPG 5.6 mmol/L or previously diagnosed type 2 DM 
3. Systolic BP 130 mmHg or diastolic BP 85 mmHg 
4. Fasting plasma triglyceride (TG) 1.7 mmol/L 
5. HDL-C <1.3 mmol/L (100 mg/dL) 
 
2.5.3 Definition of MetS in adolescent 
 
IDF does not recommend a diagnostic category for Mets in children < 10 years of 
age.  Based on the IDF definition (Zimmet et al. 2007), MetS in adolescent was 
defined as three or more of five risk factors as follow: 
1. WC ≥ age- and gender-specific 90th percentile of a local Chinese population 
(Sung et al. 2008a) 
2. FPG 5.6 mmol/L 
3. Systolic BP or diastolic BP ≥ 90th percentile (using age- and gender-specific 
reference range of our local population) (Sung et al. 2008b) 
4. Fasting plasma triglyceride (TG) 1.7 mmol/L 
5. High density lipoprotein cholesterol (HDL-C) <1.03 mmol/L 
 
Overweight was defined as BMI ≥ age- and gender-specific 90th percentile of our 




2.6 Determination of insulin resistance and pancreatic beta cell function 
 
2.6.1 Definition of insulin resistance 
 
Insulin resistance is defined as a condition of reduced insulin sensitivity in which 
the ability of insulin to lower circulating glucose is impaired.  The observations of 
insulin resistance among relatives of type 2 DM patients suggest a genetic 
association but the genetic predisposition for the development of insulin resistance 
remains uncertain.  Early insulin resistance usually results in compensatory 
increase in insulin secretion with the maintenance of euglycaemia.  At this stage, 
measurement of fasting and random glucose is often within normal range. 
 
2.6.2 Definition of pancreatic beta cell function 
 
Pancreatic beta cell function refers to the insulin secretion in response to glucose 
stimulation.  In general, insulin response is divided into first phase and second 
phase insulin secretion.  It is well accepted that pathophysiology of type 2 DM 
involves progressive beta cell dysfunction, which could involve a decrease in beta 
cell mass and/or beta cell malfunction.  Recent studies by Butler et al. (2003) on 
pancreatic tissue from autopsies showed that beta cell mass reduced through a 
mechanism of increased beta cell apoptosis.  Figure 2.2 shows the relationship 
between insulin resistance, beta cell dysfunction and progression from normal to 
DM (Chavez & Henry 2006).  Insulin resistance gradually increases while beta cell 
function initially rises up and declines as subject gradually develops into IGT and 
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DM.  Tabák et al. (2009) recently confirmed this objection on a cohort of 6538 
subjects in Whitehall II study, showing that beta cell function declines at about 2 
years prior to the occurrence of DM.   
 
Figure 2.2 Schematic diagram depicts the relationship between insulin resistance, 













2.6.3 Measurement of insulin resistance and pancreatic -cell function 
 
The gold standard for assessing insulin resistance is the hyperinsulinaemic-
euglycaemic clamp technique first described by DeFronzo and colleagues (1979).  
It is so-called because it measures the amount of glucose necessary to compensate 
for an increased insulin level without causing hypoglycaemia. During the 
procedure, insulin is usually infused at a rate of 10-120 mU per m2 per minute.  In 





Normal    IGT    DM 
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blood sugar levels between 5 and 5.5 mmol/l. The plasma glucose concentration is 
held constant by a variable glucose infusion using a negative feedback principle. 
Under these steady-state conditions of euglycaemia, the glucose infusion rate 
equals glucose uptake by all the tissues in the body and is therefore a measure of 
tissue sensitivity to exogenous insulin.  Subject who is insulin-sensitive requires a 
higher level of glucose infusion while subject who is insulin resistant requires a 
low level.  The procedure takes about 2 hours and is rather complex and labour 
intensive to allow its use in routine clinical practice. 
 
Another well accepted alternative for estimating insulin sensitivity is a minimal 
model analysis of a frequently sampled intravenous glucose tolerance test 
(FSIVGTT) (Foley et al. 1985).  Although less labour intensive than the clamp 
technique, FSIVGTT usually still requires 11 to 34 blood samples over 3 hours.  
Nonetheless, there are several surrogate measures of insulin resistance on the basis 
of plasma glucose and insulin levels which are simpler and correlate well the gold-
standard techniques.  Homeostasis Model Assessment of Insulin Resistance 
(HOMA-IR) which based on fasting glucose and insulin levels had been widely 
applied to measure insulin resistance (Matthews et al. 1985).  The estimation of 
insulin resistance from HOMA-IR correlated strongly with that estimated by the 
clamp technique (Matthews et al. 1985).  Furthermore, Matsuda insulin sensitivity 
index (Matsuda-ISI) (Matsuda & DeFronzo 1999, Kuo et al. 2002) and 
Quantitative Insulin Sensitivity Check Index (QUICKI) (Katz et al. 2000; Chen et 
al. 2003) were also found to have good correlation with insulin resistance 
determined by the clamp method. 
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Similar to the insulin resistance, the gold standard for assessing beta cell function is 
also based on the hyperglycaemic clamp technique (DeFronzo and colleagues 
1979).  The estimation of deficient beta-cell function obtained by homeostasis 
model assessment (HOMA-BCF) was found to have a moderate correlation with 
that derived using the clamp technique and FSIVGTT (Matthews et al. 1985).  
Stumvoll & colleagues (2000) demonstrated that beta cell function as reflected by 
the first phase and second phase insulin release during the hyperglycaemic clamp 
studies could largely be predicted by the 0- and 30- min plasma insulin value and 
the 30-min glucose value during the OGTT – the insulinogenic index.  On the other 
hand, Bacha et al. (2008) showed the ratio of the incremental response of insulin to 
glucose at 15 and 30 minutes during an OGTT correlate with the first phase insulin 
secretion and the area under the curve (AUC) of insulin during an OGTT correlate 
with the second phase insulin secretion. 
 
The 5 point OGTT with insulin assay performed for the mother and children at the 
8 year follow up enable the assessment of insulin resistance and pancreatic beta cell 
function with the following formula. 
 
Insulin resistance was calculated using the following formula:  
 
1. HOMA-IR = I0 (μU/ml) × G0(mmol/L) / 22.5 (Matthews et al. 1985); 
2. Matsuda-ISI = 10000/ √ (G0 (mg/dL) × I0 (μU/ml)) × (G (mg/dL)× I (μU/ml)) 
(Matsuda & DeFronzo 1999);  
3. QUICKI = 10 / (log I0 (μU/ml) + log G0(mg/dL)) (Katz et al. 2000);  
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Pancreatic -cell function was determined as: 
1. AUC(I) (pmol/L) /AUC(G) (mmol/L) (Stumvoll et al. 2000) 
2. HOMA-BCF = I0(μU/ml)× 20 / (G0 (mmol/L) – 3.5) (Matthews et al. 1985) 
3. Insulinogenic index at 15 minutes of the OGTT 
(I15– I0) (pmol/L) / (G15 – G0) (mmol/L) (Stumvoll et al. 2000) 
4. Insulinogenic index at 30 minutes of the OGTT 
(I30– I0) (pmol/L) / (G30 – G0) (mmol/L) (Stumvoll et al. 2000)  
where [G0,G15,G30,G  & AUC (G) = fasting, 15 minute, 30 minute, mean PG levels 
and the area under the PG level-time curve from 0 minutes to 120 minutes in the 
OGTT and I0,I15,I30, I & AUC (I) = fasting, 15-minute, 30-minute, mean insulin 
levels and the area under the plasma insulin level-time curve from 0 minutes to 120 
minutes in the OGTT respectively]. 
Furthermore, the insulin secretion/insulin resistance (disposition) index calculated 
as the product of insulin secretion measured with insulinogenic index and Matsuda-
ISI had excellent power to predict onset of type 2 DM (Abdul-Ghani et al. 2007). 
Disposition index which assess the acute insulin response in relation to the level of 
insulin sensitivity is defined as:  
 (I30– I0) (pmol/L) / (G30 – G0) (mmol/L) × Matsuda-ISI (Abdul-Ghani et al. 2007) 
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2.7 Statistical analysis 
 
2.7.1 Statistical programme 
 
All statistical analysis was performed by using Statistical Package for Social 
Science (SPSS) for Windows version 13.0–17.0 (SPSS, Chicago, IL). The 
statistical programme - Analyse-it version 2.09 (Analyse-it Software, Ltd.), 
which is an add-in programme for Microsoft Excel, was used for the Receiver 
Operator Characteristics (ROC) analysis described in this Chapter 4 and 6.  
 
2.7.2 Comparison between group differences 
 
The studies were designed to compare the difference in clinical and biochemical 
parameters between 2 groups of subjects: mothers who had NGT vs. mothers who 
had gestational diabetes at the index pregnancy (Chapter 3), as well as the offspring 
of mothers who had NGT vs. those of mothers who had gestational diabetes 
(Chapter 5) at both 8 and 15 years after delivery. 
 
Data which are continuous variables were, in general, expressed as means and 
standard deviations with an assumption that they were normally distributed.  
Independent Samples t-test was used to compare the continuous variables between 
groups.  On the other hand, data which are categorical were expressed as frequency 
(the number) and percentage, and Chi-square test was used to compare the 
difference between groups.  However, the use of the continuous Chi-squared 
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distribution to approximate frequencies may introduce bias into the calculation 
when the sample sizes are small.  Therefore, in situation where the frequency of 
outcome fell below 5, Fisher’s exact test was used to compare the group difference.  
Fisher’s exact test was used in Table 3.1, Table 3.2 and Table 5.3. 
 
2.7.3 General Linear Model (GLM) 
 
At the 8 year follow up assessment (described in Chapter 5), children of mothers 
with NGT were found significantly older than those of mothers with gestational 
diabetes (mean age 8.4 vs. 7.7 years, p <0.001).  The male: female ratios among 
children of mothers with NGT also appeared greater than that children of mothers 
with gestational diabetes but it did not reach statistical significance (1.20 vs. 0.70, p 
= 0.10) (Tables 5.1 & 5.2). 
 
In order to adjust the effect of age and potential gender difference, univariate 
General Linear Model (GLM) was used to compare the group difference on the 
children’s anthropometric indices, blood pressures and biochemical parameters at 
the 8 year-follow up assessment. 
 
A GLM is “general” in the sense that one may implement both regression and 
analysis of variance (ANOVA) models.  A univariate GLM is a test which applies 
to only one dependent variable which is numeric (refers here to the clinical and 
biochemical parameters of interest in Chapter 5) and can be one or more 
independent variables or factors.  In our own setting, we put maternal gestational 
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diabetes status as a fixed factor, children’s age as a covariate and gender as a 
random factor.  Therefore, variables were expressed as adjusted means and 
standard error of mean (SEM) (Table 5.2). 
 
2.7.4 Multivariate logistic regression 
 
In Chapter 3, Chapter 5 and Chapter 6, logistic regression was used to assess the 
prediction of cardiometabolic risk, namely AGT, DM, MetS and hypertension, on 
the basis of various continuous and categorical independent variables.  In contrast 
to a linear regression which has a continuous dependent variable, logistic 
regression is used when the dependent variable is a dichotomy (binary logistic 
regression) or more than 2 classes (multinomial logistic regression). In the thesis, it 
was confined to a binary logistic regression in which the dependent variable of 
interest is the presence or absence of an “event” (which refers to cardiometabolic 
risk). 
 
In a binary logistic equation, the “event” is coded as either 0 or 1.  By default, 
event “equals 1” and the reference category “equals 0”.  After the “event” is 
transformed into a logit variable (the natural log of the odds of the “event”), 
logistic regression estimates the odds of its occurrence.  The impact of predictor 




The natural log of the odds of an event equals the natural log of the probability of 
the condition occurring divided by the probability (prob) of the event not occurring:  
ln [odds (event)] = ln [prob (event) / prob (non-event)]  
The logistic regression equation is expressed as:  
z  = b0 + b1X1 + b2X2 + ..... + bkXk  
where z is the log odds of the dependent variable = ln [odds(event)],  
b0 is the constant and there are k independent (X) variables, some of which may be 
interaction terms.  
The “b” terms are the logistic regression coefficients, also called parameter 
estimates;  
Exp (b) [the natural log base e raised to the power of b] is the odds ratio for an 
independent variable. 
 
We used Hosmer and Lemeshow goodness-of-fit test (also known as Hosmer and 
Lemeshow chi-square test of goodness-of-fit) to assess the overall model fit of the 
logistic regression model. This test is considered more robust than the traditional 
chi-square test, particularly if continuous covariates are in the model or sample size 
is small (Garson 2010).  
 
The Hosmer and Lemeshow goodness-of-fit test divides subjects into deciles based 
on predicted probabilities, then computes a chi-square from observed and expected 
frequencies.  Then a probability (p) value is computed from the chi-square 
distribution with 8 degrees of freedom to test the fit of the logistic model, as 
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illustrated in Table 2.1 based on an example analysis reported in Table 6.2 of 
Chapter 6  
 
If the Hosmer and Lemeshow goodness-of-fit test statistic is > 0.05, null hypothesis 
that there is no difference between observed and model-predicted values, implying 
that the model's estimates fit the data at an acceptable level. That is, well-fitting 
models show non-significance on the Hosmer and Lemeshow goodness-of-fit test, 
indicating model prediction is not significantly different from observed values. 
 
The Wald statistic, which is squared ratio of the unstandardised logistic coefficient 
to its standard error, is an alternative test used to test the significance of individual 
logistic regression coefficients for each independent variable.  If the Wald statistic 
is significant (i.e.< 0.05), then the parameter is significant in the model.  The 
“Exp(B)” is the odds ratio of the independent with the event (adolescent MetS in 
this example).  An odds ratio <1 corresponds to a decrease and odds ratio > 1 
corresponds to an increase in odds. 
 
Logistic regression is used to assess the prediction of mother’s and children’s 
cardiometabolic risk on the basis of different independent variables in Chapter 3, 
Chapter 5 and Chapter 6. 
 
 36 
Table 2.1 Sample SPSS output of the Hosmer and Lemeshow goodness-of-fit test 
used in the prediction of MetS at 15 years of age on the basis of cord C peptide levels 
above 90th percentile reported in table 6.2 
Contingency Table for Hosmer and Lemeshow Test 
 
MetS of children at = Normal MetS of children = MetS 
Total Observed Expected Observed Expected 
Step 1 1 8 8.000 0 .000 8
2 8 8.000 0 .000 8
3 8 8.000 0 .000 8
4 8 7.966 0 .034 8
5 8 7.919 0 .081 8
6 8 7.852 0 .148 8
7 8 7.757 0 .243 8
8 7 7.581 1 .419 8
9 7 7.164 1 .836 8
10 5 4.761 2 2.239 7
Hosmer and Lemeshow Test 
Step Chi-square df Sig. 
1 1.440 8 .994
Variables in the Equation 
 
B S.E. Wald df Sig. Exp(B) 
95% C.I.for EXP(B) 
Lower Upper 
Step 1a C_peptide90 2.869 1.321 4.714 1 .030 17.624 1.322 234.939
M_GDM(1) -.215 1.376 .025 1 .876 .806 .054 11.951
C_Tanner   .484 3 .922    
C_Tanner(1) .397 15778.852 .000 1 1.000 1.488 .000 .
C_Tanner(2) 19.033 13551.785 .000 1 .999 1.844E8 .000 .
C_Tanner(3) 20.083 13551.785 .000 1 .999 5.270E8 .000 .
Birthwt -.002 .002 1.304 1 .253 .998 .995 1.001
M_BMI .216 .180 1.440 1 .230 1.241 .872 1.767
Constant -21.620 13551.786 .000 1 .999 .000   




2.7.5 Receiver operating characteristic (ROC) analysis 
 
ROC analysis was used to compare the predictability of several glycaemic indices 
in mid-gestation of the index pregnancy, namely FPG & 2-h PG of the 75 gram 
OGTT and GCT on women’s progression to AGT, DM, hypertension and MetS in 
Chapter 4.  We also use ROC analysis to assess the prediction of cord blood insulin 
level on childhood AGT at 8 years age in Chapter 5. 
 
Figure 2.3 depicts a hypothetical example of subjects’ glycaemic levels between 
those with a positive and those with a negative outcome.  A perfect predictive test 
implies that there should be no overlap in levels between the two groups, resulting 
in an optimal cut-off threshold which can distinguish completely those with 
positive and negative outcomes.  But in real practice, there is always some degree 
of overlap between the two groups.  In this figure, cases in the negative group with 
glycaemic levels above a chosen cut-off threshold become false positive (solid grey 
dots) while those in the positive group with glycaemic levels below the threshold 
become false negative (solid black dots).  The true positive rate (sensitivity) of a 
test can be increased by lowering the threshold but at a trade-off of increasing the 
false positive rate (1-specificity). 
 
The data can be expressed as a ROC curve (Hanley & McNeil 1982) which is a 
graphical plot between the sensitivity and 1-specificity for each possible cut-off in 
the prediction of an outcome (referring to DM, AGT, hypertension and MetS in our 
studies) as shown in Figure 2.4. 
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Figure 2.3 A hypothetical distribution of glycaemic levels among subjects with a 
positive and negative outcome 




























A predictive test that perfectly discriminates between the two groups would yield a 
curve that coincide with the left and top sides of the plot while a test that is 
completely useless would give a straight line from the bottom left corner to the top 
right corner, named as the line of non-discrimination (dotted line).  Alternatively, 



















Figure 2.4  A typical ROC curve which demonstrates the inflection point and the line 
of non-discrimination
Inflection point
Line of non-discrimination 
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under the ROC curve (AUC-ROC) which ranges from 0.5 (non-discriminatory) to 
1.0 (a perfect test).  In general, AUC-ROC between 0.5 and 0.7 indicates low, 
between 0.7 and 0.9 moderate and > 0.9 high predictability (Swets 1988). 
 
Although several approaches can be used to calculate the AUC-ROC for the 
comparison of ROC curves, nonparametric methods are preferred if the variables 
follow an ordinal or skewed distribution or if there are small samples sizes.  We 
used Delong paired test (Delong et al. 1988), provided in Analyse-it, to compare 
the AUC-ROC calculated from various glycaemic variables.  A p-value less than 
0.05 (2 tailed) was considered to be significant. 
 
The optimal cut-off should be a threshold whereby the sensitivity and specificity lie 
at the point (the inflection point of Figure 2.4) which is closest to the top left corner.  
Alternatively, the optimal threshold can be determined at a level in which Youden 
index (equals to sensitivity  specificity  1) is maximal. 
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2.8 Ethics approval 
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HISTORY OF GESTATIONAL DIABETES AND WOMEN’S FUTURE CARDIOMETABOLIC 
RISK 
 
This chapter describes the results of the study which address on the women’s future 
cardio-metabolic risk after a prior history of gestational diabetes in Chinese. 
Hypothesis 1:  
Chinese women with prior history of gestational diabetes had increased 
cardiometabolic risk 
 
3.1 Maternal clinical parameters at the index pregnancy 
 
The median period of the first follow up was 8 years (range: 7–10 years) since the 
delivery of the index pregnancy.  Amongst the 402 women selected from the 
original cohort, 203 women (response rate = 50.5%) completed the follow up 
evaluation.  Majority of the women (160 women) were not contactable by both 
telephone and postal contact while 39 of them could be contacted but decline to 
participate. 
 
The maternal age, nulliparity, family history of DM and maternal BMI at booking 
visit between the responders (27.8  4.4 years, 56.2%, 15.3% and 24.5  3.1 kg/m2) 
and the non-responders (28.2  4.7 years, 60.9%, 16.8% and 24.5  3.1 kg/m2) 
were similar at the index pregnancy (all p-values >0.05). 
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Table 3.1 shows the mothers’ clinical parameters during the index pregnancy 
stratified by their gestational diabetic status.  There was no significant difference in 
the maternal age, BMI, family history of DM and the neonatal outcome.  The 
glycaemic variables at the index pregnancy, namely GCT, FPG & 2-h PG of the 
OGTT (as described in Chapter 2) were significantly higher among mothers with 
gestational diabetes.  None of the subjects had hypertension prior to their 
pregnancy except three women who developed gestational hypertension and one 
woman had pre-eclampsia. 
 
3.2 Maternal cardiometabolic status at 8 years post-delivery 
 
Amongst the 203 women, 136, 63 and 4 had NGT, GIGT and GDM (as defined in 
Chapter 2) respectively at the index pregnancy.  A total of 51 (25%) women 
developed AGT at the 8 year follow up.  In women with NGT during the index 
pregnancy, 21 (15.4%) developed IGR and 3 (2.2%) developed DM.  In the GIGT 
group, the respective figures were 19 (30.2%) and 4 (6.3%) and in the GDM group 





Table 3.1 Mothers’ clinical parameters at the index pregnancy stratified by their 






(n = 136) 
Gestational diabetes 
(n = 67) 
p§ 
Obstetric data:    
Maternal age (years) 27.4 (4.3) 28.6 (4.3) 0.07 
Nulliparity 74 (54.4) 40 (59.7) 0.39 
Body weight (kg) 54.4 (8.3) 55.3 (8.8) 0.48 
Body mass index (kg/m2) 24.4 (2.7) 24.8 (3.6) 0.20 
Family history of diabetes (%) 18 (13.2) 13 (19.4) 0.25 
50 gram GCT, 1-h PG (mmol/L) 6.5 (1.5) 7.9 (1.8) <0.001 
75 gram OGTT, FPG (mmol/L) 4.0 (0.6) 4.5 (0.6) <0.001 
75 gram OGTT, 2-h PG (mmol/L) 5.8 (1.0) 8.8 (1.3) <0.001 
Neonatal outcome:    
Gestational week at delivery (weeks) 39.5 (1.6) 39.3 (2.1) 0.54 
Neonatal birth weight (g) 3272 (429) 3230 (485) 0.26 
Lifebirth with 5 minute Apgar score <7 0 1 (1.5) 0.32† 
Stillbirth 0 1 (1.5) 0.32† 
 
§p-values comparing those with NGT and gestational diabetes by using the Student’s t-test, Chi-square 
where appropriate; †Analysis was performed with Fisher exact test. 
1-h, 1-hour; 2-h, 2-hour; FPG, fasting plasma glucose; GCT, glucose challenge test; NGT, normal 




Table 3.2 shows the mothers’ cardiometabolic status at the 8-year follow up.  All 
data are expressed as mean (standard deviation) or number (%). Between-group 
comparisons were made using the chi-square test or Fisher’s exact test for 
categorical and student’s t-test for continuous variables as appropriate. 
 
There was no significant difference in subjects’ age at the follow up and the rate of 
subsequent pregnancies. Although there seems a trend of higher rate of gestational 
diabetes in the subsequent pregnancies amongst those with gestational diabetes at 
the index pregnancy, it did not reach statistical significance.  The rate of IGR 
(31.3% vs. 15.4%; p = 0.003) and DM (9% vs. 2.2%; p = 0.017) were significantly 
higher among mothers with gestational diabetes than mothers with NGT during 
pregnancy; 86% of women with IGR (n = 36) and 78% of those with DM (n = 7) 
were undiagnosed prior to the follow up evaluation.  Women with history of 
gestational diabetes had also higher BP and lower HDL-C than women with NGT 
during pregnancy but the rates of MetS were similar between the 2 groups (Table 
3.2). 
 
Although the rate of MetS did not differ between the two groups, mothers with 
gestational diabetes did have a significantly higher rate of components of MetS, 
namely rate of reduced HDL-C (31.3% vs. 15.4%), raised systolic BP (22.4% vs. 
8.1%) and diastolic BP (17.9% vs. 7.4%).  The rates of central obesity and raised 




Table 3.2 Mothers’ cardiometabolic status at 8-year follow up stratified by their 






(n = 136) 
Gestational diabetes 
(n = 67) 
p§ 
Age at follow up 36.3 (4.7) 36.9 (4.4) 0.40 
Subsequent pregnancies:         1 59 (50.0) 26 (38.2) 0.32 
       ≥2 10 (41.9) 2 (2.9) 0.15 
Subsequent pregnancies with gestational diabetes 3 (4.3) 5 (17.8) 0.04† 
Family history of diabetes (%) 35 (25.7) 28 (41.2) 0.04 
Body mass index (kg/m2) 23.7 (3.5) 24.4 (4.6) 0.24 
Glycaemic status:    
 IGR (IFG and/or IGT) 21 (15.4) 21 (31.3) 0.003 
 DM 3 (2.2) 6 (9.0) 0.017† 
Metabolic syndrome (%) 11 (8.1) 5 (7.5) 0.85 
Waist circumference ≥80 cm (%) 32 (23.5) 14 (20.9) 0.64 
Systolic BP ≥ 130 mmHg 11 (8.1) 15 (22.4) 0.004 
Diastolic BP ≥ 85 mmHg 10 (7.4) 12 (17.9) 0.023 
Triglyceride ≥ 1.7 mmol/L 10 (7.4) 8 (11.9) 0.28 
HDL-C < 1.3 mmol/L 21 (15.4) 21 (31.3) 0.009 
 
§p-values comparing those with NGT and gestational diabetes using the Student’s t-test, Chi-square 
or †Fisher exact test where appropriate. 
BP, blood pressure; DM, diabetes mellitus; HDL-C, high density lipoprotein cholesterol; IGR, 
impaired glucose regulation, IGT, impaired glucose tolerance; IFG, impaired fasting glycaemia; 
NGT, normal glucose tolerance. 
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3.3 Maternal cardiometabolic status at 15 years post-delivery 
 
Since the 8 year follow up evaluation, 2 women died from causes unrelated to DM 
or hypertension (1 died of acute GI bleeding and another died in the Accident and 
Emergency Department of an acute illness); 47 women refused to participate the 15 
year follow up evaluation and 16 women could not be contacted.  Finally, 139 
(68.4%) of the previous cohort (94 with NGT and 45 with gestational diabetes) 
completed the 15-year follow up evaluation. 
 
The maternal age, maternal BMI at booking and gestational diabetic status visit 
between the responders (28.0  4.3 years, 22.6  3.3 kg/m2 and 32.4%) and the 
non-responders (27.4  4.5 years, 22.2  3.3 kg/m2 and 35.4%) were similar at the 
index pregnancy (all p-values >0.05).  When compared to the follow up assessment 
at 8 year post-delivery, type 2 DM increased from 2.2% to 5.3% (2.4-fold increase) 
and from 9% (n= 6/67) to 24.4% (n= 11/45; 2.7-fold increase) among the women 
with NGT during pregnancy and gestational diabetes respectively. 
 
Amongst the 6 women who were known to have type 2 DM before the 15 year 
follow up, 5 were actually diagnosed during the 8 year follow up study DM while 1 
was diagnosed IGT at the time. Four of them were subsequently put on oral 
hypoglycaemic drug treatment.  The remaining 10 (62.5%) women with Type 2 
DM were undiagnosed prior to the 15 year study.  Hypertension occurred in 31 
(22%) subjects in the cohort and 10 (32.3%) of them were also undiagnosed. 
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Table 3.3 shows the mothers’ cardiometabolic status at the 15-year follow up.  
Women with a prior history of gestational diabetes and women with NGT were of 
similar age, parity, smoking habit, body weight and BMI at a median follow up of 
15 years after the index pregnancy. Women with prior history of gestational 
diabetes had significantly higher prevalence of hypertension (35.6% vs. 16.0%, 
p = 0.01), type 2 DM (24.4% vs. 5.3%, p < 0.001) and IGR (26.6% vs. 14.9%, 
p < 0.001), as well as higher plasma triglyceride levels (1.33 ± 0.80 mmol/L vs. 
1.06 ± 0.57 mmol/L, p = 0.03) than women with NGT. There were no significant 
differences in plasma levels of other lipids and the prevalence of MetS between the 
2 groups.  There was no case of myocardial infarction, cardiovascular accident and 
renal failure occurred in the cohort at both follow up. 
 
3.4 Prediction of cardiometabolic risk by maternal gestational diabetic 
status 
 
Multivariate logistic regression analysis was used to obtain adjusted OR with 95% 
confidence intervals (CI), with forced entry of gestational diabetic status, advanced 
maternal age, family history of DM and BMI ≥23 kg/m2 during the index 
pregnancy as independent variables.  Stepwise algorithm (p = 0.10 for entry and 
0.05 for removal) was used to select other variables.  Model fit was assessed using 
the Hosmer and Lemeshow Goodness-of-Fit test.  A p-value <0.05 for two-tailed 




Table 3.3 Mothers’ cardiometabolic status at 15-year follow up stratified by their 
status of a past history of gestational diabetes 
 
 NGT  (n = 94) 
Gestational diabetes 
(n = 45) p 
Age at follow up 43.2 (4.6) 43.8 (4.3) 0.49 
Parity 
1 10 (10.6%) 9 (20.0%) 
0.22 ≥ 2 84 (89.4%) 36 (80.0%) 
Current smoker 9 (9.3%) 2 (4.8%) 0.53 
Body weight (kg) 59.1 (9.5) 59.0 (10.2) 0.97 
Body height (cm) 155 (6) 155 (6) 0.49 
Body mass index (BMI) (kg/m2) 24.4 (3.5) 24.7 (4.5) 0.70 
Waist circumference (cm) 81.5 (9.7) 82.5 (10.4) 0.60 
Hip circumference (cm) 98.3 (7.1) 98.03 (7.2) 0.85 
Waist-Hip ratio 0.82 (0.08) 0.84 (0.06) 0.22 
Hypertension 15 (16.0%) 16 (35.6%) 0.01 
Fasting plasma glucose (mmol/L) 4.9 (0.5) 5.4 (0.9) 0.002 
2hr-plasma glucose (mmol/L) 6.4 (2.1) 8.1 (2.9) 0.001 
Maternal glycaemic 
status at follow up 
NGT 75 (79.8%) 22 (48.9%) 
<0.001 IFG &/or IGT 14 (14.9%) 12 (26.6%) 
DM 5 (5.3%) 11 (24.4%) 
HDL-C (mmol/L) 1.59 (0.35) 1.49 (0.33) 0.12 
LDL-C (mmol/L) 2.68 (0.80) 2.72 (0.61) 0.75 
Triglyceride (mmol/L) 1.06 (0.57) 1.33 (0.80) 0.03 
Total cholesterol (mmol/L) 4.73 (0.84) 4.79 (0.58) 0.69 
Metabolic syndrome (%) 14 (14.9%) 10 (22.2%) 0.41 
 
Data was expressed in either mean (SD) or number (%). 
DM, diabetes mellitus; HDL-C, high density lipoprotein cholesterol; IGR, impaired glucose 
regulation; IGT, impaired glucose tolerance; IFG, impaired fasting glucose; LDL-C, low density 




3.4.1 AGT and MetS at 8 years by maternal gestational diabetic status 
 
Table 3.4 showed the number of women with and without AGT and MetS at 8 
years and their odds ratio.  In a multivariate model, gestational diabetes and BMI 
≥23kg/m2 at booking increased the odds of developing AGT at 8 years by 3.8 (95% 
CI 1.9–7.8) and by 3.4 (95% CI 1.7–6.8) respectively.  On the other hand, family 
history of DM and BMI ≥23kg/m2 at booking were significant predictors of MetS 
at 8 years with ORs of 5.0 (95% CI 1.5–16.4) and 28.3 (95% CI 3.6–223) 
respectively. 
 
3.4.2 AGT, DM, hypertension and MetS at 15 years by maternal gestational 
diabetic status 
 
Table 3.5 shows the results of multivariate logistic regression analysis on the 
prediction of AGT, DM, hypertension and MetS at 15 year by using gestational 
diabetic status, advanced maternal age, family history of DM and BMI ≥23 kg/m2 
during the index pregnancy as independent variables.  History of gestational 
diabetes increased the odds (95% CI) of developing AGT, DM and hypertension by 
5.2 (2.2-12.1), 8.0 (2.2-28.3) and 3.3 (1.4-7.8) respectively.  After adjustment for 
the conversion of type 2 DM, maternal gestational diabetic status was still 
predictive of women’s hypertension at 15 years post-delivery [odds ratio (95% CI): 
2.5 (1.0-6.2)].  
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Table 3.4 Pregnancy-related variables in women who developed abnormal glucose tolerance (AGT) and metabolic syndrome (MetS) at 8 
year follow up 
 
 Glycaemic status MetS 
 NGT (n = 152) 
AGT 




(n = 187) 
MetS 
(n = 16) 
Adjusted OR 
(95% CI) 
Gestational diabetes 40 (26.3%) 27 (52.9%) 3.8 (1.9–7.8) 62 (33.5%) 5 (31.3%) 0.9 (0.3–2.7) 
Advanced maternal age 8 (5.3%) 8 (15.7%) 2.9 (1.0–8.7) 13 (7.1%) 3 (18.8%) 3.0 (0.7–12.0) 
Family history of DM 21 (13.9%) 10 (19.6%) 1.5 (0.7–3.5) 24 (13.0%) 7 (43.8%) 5.0 (1.5–16.4) 




Table 3.5 Pregnancy-related variables in women who developed abnormal glucose tolerance (AGT), DM, hypertension (HT) and 
metabolic syndrome (MetS) at 15 years post-delivery 
 
 
 AGT DM HT MetS 
Gestational diabetes 5.2 (2.2–12.1) 8.0 (2.2–28.3) 3.3 (1.4–7.8)* 2.1 (0.8–5.6) 
Advanced maternal age 2.5 (0.6–10.6) 5.0 (0.9–28.1) 1.4 (0.3–6.2) 0.8 (0.1–4.0) 
Family history of DM 2.8 (1.1–7.6) 2.4 (0.7–8.6) 2.4 (0.9–6.5) 2.3 (0.8–6.7) 
BMI at booking ≥ 23 kg/m2 2.3 (1.0–5.3) 2.2 (0.7–7.2) 2.1 (0.9–5.0) 6.0 (2.1–17.2) 
 
Data are expressed as adjusted odds ratio (95% CI) 
*Odds ratio after adjusted for conversion to type DM: 2.5 (1.0–6.2) 
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3.5 The role of insulin resistance in predicting women’s DM and MetS 
 
Table 3.6 summarises the results of the logistic regression on the prediction of type 
2 DM at 15 years with age, BMI, gestational diabetic status at index pregnancy, 
AGT status at 8 years, Matsuda-ISI, beta-cell function and insulinogenic indices. 
Insulin sensitivity indices, represented by Matsuda-ISI and QUICKI, remained 
independent predictors of both DM and MetS at 15 years post-delivery, with or 
without adjustment for beta cell function and or AGT status at 8 years post-delivery.  
The same findings cannot be reproduced with the insulin resistance measured by 
HOMA model. 
 
Insulinogenic index at 15 minutes at 8 years post-delivery was found to be a 
predictor of MetS at 15 years but not predictor of type 2 DM. There is a trend that 
beta cell function at 8 years, represented by HOMA-BCF, being predictive of DM 
at 15 years, adjusting for insulin sensitivity, but does not research statistical 
significance.  Gestational diabetic status during pregnancy remained an 
independent predictor of DM at 15 years post-delivery but not a predictor of MetS 
after adjustment for insulin resistance and beta cell function. 
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Table 3.6 The prediction of type 2 DM and metabolic syndrome (MetS) at 15-year 
post-delivery using logistic regression with gestational diabetic status at index 
pregnancy, insulin sensitivity indices, beta-cell function and insulinogenic indices at 
8-year post-delivery after adjustment for age, BMI and AGT status at 8 years. 
 
 DM at 15 years p MetS at 15 years p 
Matsuda-ISI 0.55 (0.36–0.84) 0.006 0.66 (0.49–0.88) 0.005 
Matsuda-ISI† 0.38 (0.20–0.70) 0.002 0.59 (0.41–0.85) 0.004 
Matsuda-ISI*† 0.43 (0.23–0.82) 0.010 0.62 (0.43–0.89) 0.009 
QUICKI 0.14 (0.026–0.74) 0.021 0.17 (0.042–0.68) 0.012 
QUICKI† 0.015 (0.001–0.26) 0.004 0.078 (0.011–0.55) 0.011 
QUICKI*† 0.028 (0.01–0.78) 0.035 0.11 (0.015–0.79) 0.028 
HOMA-IR 1.08 (0.90–1.30) 0.43 1.05 (0.88–1.26) 0.56 
HOMA-IR† 1.35 (0.89–2.06) 0.16 1.04 (0.79–1.37) 0.77 
HOMA-IR*† 1.11 (0.71–1.74) 0.64 0.97 (0.73–1.30) 0.86 
AUC(I)/AUC(G) 1.00 (0.98–1.01) 0.71 1.00 (1.00–1.02) 0.18 
AUC(I)/AUC(G)‡ 1.11 (0.95–1.30) 0.20 1.06 (0.94–1.21) 0.34 
AUC(I)/AUC(G)*‡ 1.08 (0.93–1.26) 0.32 1.06 (0.93–1.20) 0.41 
HOMA-BCF 1.00 (1.00–1.00) 0.95 1.00 (1.00–1.00) 0.62 
HOMA-BCF‡ 0.99 (0.99–1.00) 0.058 1.00 (0.99–1.00) 0.25 
HOMA-BCF*‡ 0.99 (0.99–1.00) 0.058 1.00 (0.99–1.00) 0.30 
Insulinogenic index 30 min 1.02 (0.82–1.27) 0.84 1.02 (0.88–1.19) 0.80 
Insulinogenic index 30 min‡ 0.98 (0.85–1.13) 0.80 1.00 (0.89–1.12) 0.99 
Insulinogenic index 30 min*‡ 0.99 (0.74–1.31) 0.94 1.00 (0.89–1.14) 0.96 
Insulinogenic index 15 min 1.03 ( 0.83–1.27) 0.80 1.79 (1.14–2.82) 0.012 
Insulinogenic index 15 min‡ 1.01 (0.75–1.35) 0.95 1.86 (1.12–3.07) 0.016 
Insulinogenic index 15 min*‡ 1.11 (0.63–1.95) 0.73 1.65 (1.07–2.55) 0.023 
Disposition index 1.00 (0.95-1.05) 0.93 0.99 (0.97-1.01) 0.99 
Gestational diabetes‡ 5.29 (1.47–19.1) 0.011 0.87 (0.30–2.49) 0.79
Gestational diabetes§ 5.67 (1.66–19.4) 0.006 1.04 (0.37–2.93) 0.94 
Gestational diabetesδ 5.01 (1.56–16.1) 0.007 1.23 (0.45–3.40) 0.69 
     
 
 
Data was expressed in Odds ratio (95% CI). 
 
i) Prediction by all insulin sensitivity, insulin resistance indices and beta cell functions were adjusted for maternal 
age, BMI at booking during pregnancy and gestational diabetic status, together with *adjustment for abnormal 
glucose tolerance at 8 year follow up, or †adjustment for HOMA-BCF, or ‡ adjustment for Matsuda-ISI; 
ii) Prediction by gestational diabetes were adjusted for maternal age, BMI at booking during pregnancy and 
together with ‡adjustment for Matsuda-ISI, or ‡adjustment for §QUICKI, or δadjustment for HOMA-BCF. 
AUC-(G), Area under the curve of glucose level at OGTT; AUC (I), Area under the curve of insulin level at OGTT; 
HOMA-BCF, homeostasis model assessment of beta cell function; HOMA-IR, homeostasis model assessment of 





In this first prospective study to examine the effects of gestational diabetes on 
women’s future cardiometabolic risk in Chinese, we demonstrated high rates and 
increased risk of DM, IGR and MetS in agreement with data from Caucasians (Kim 
et al. 2002; Cheung et al. 2003).  
 
In this cohort of Chinese women who were relatively young at a mean age of 28 
years during pregnancy in which gestational diabetes was diagnosed by universal 
OGTT, type 2 DM increases by about 2.5 fold from 9% at 8 years to 24.4% at 15 
years post-delivery. 
 
Although we did encourage women with history of gestational diabetes to visit 
their family doctors for repeat OGTT 6 weeks after delivery, we do not have a 
system in Hong Kong to ensure compliance with this recommendation.  Majority of 
women with DM or IGR were undiagnosed at the time of the follow up study.  
Given their young age and long disease duration if affected, missed diagnosis of 
DM can have major consequences.  Thus, our prospective data further emphasize 
the need to target these high risk women for regular screening and surveillance. 
 
In agreement with most findings (Albareda et al. 2003; Dalfra et al. 2003; Henry & 
Beischer 1991), a history of gestational diabetes and overweight at booking were 
predictors for IGR and DM.  However, contrary to other findings (Dalfra et al. 
2001; Aberg et al. 2002), advanced maternal age and family history of DM at the 
 58 
time of index pregnancy were not found to be risk factors in our study.  This might 
be in part due to the age-matching strategy in our selection of control subjects. 
Although the two groups reported a positive family history of DM, with similar 
frequency during their index pregnancy, women who subsequently developed AGT 
did report a higher rate of family history of DM at 8 years later. 
 
Despite some overlap between IGR and MetS, we found different risk factors for 
these conditions in Chinese women. In agreement with other workers (Albareda et 
al. 2005), a history of gestational diabetes was associated with increased risk of 
some components of MetS, namely hypertension and low HDL-C, but was not 
predictive of an increased frequency of MetS.  On the other hand, being overweight 
at booking and family history of DM were predictors of MetS in our cohort.  Given 
the heterogeneity of DM and MetS, more studies are required to clarify their 
natural history, phenotypes and aetiologies.  
 
Our result also showed that history of gestational diabetes increased the odds of 
future hypertension at 15 years by 3.3; the odds of hypertension remained 
significant (2.5-fold) after controlling for the occurrence of type 2 DM.  The result 
is consistent with the finding of Shah et al. (2008) who demonstrated an increased 
risk of cardiovascular disease following gestational diabetes with a hazard ratio of 
1.7 which is still significant (hazard ratio of 1.1) after adjustment for the 
development of type 2 DM.  It can be concluded from the result that women with a 
prior history of gestational diabetes had a substantial increase in the cardiovascular 
risk which was partially attributed by the subsequent development of type 2 DM. 
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We also found that overweight at booking but not gestational diabetes remained the 
most significant predictor of MetS at 15 years post-delivery.  Several follow up 
studies on women with prior history gestational diabetes had, however, 
demonstrated an increased future risk of MetS, (Kale et al. 2004; Albareda et al. 
2005; Lauenborg et al. 2005; Wender-Ozegowska et al. 2007) which in turn was 
strongly associated with cardiovascular risk (Ford 2005; Cabre et al. 2008; 
Holewijn et al. 2009).  Another study also demonstrated that some constituents of 
MetS might already be apparent before the diagnosis of gestational diabetes, 
implying a strong association between gestational diabetes and MetS (Noussitou et 
al. 2005). 
 
From a preventive perspective, given the high risk nature of these conditions for 
premature cardiovascular diseases (Ford et al. 2005) and that randomised clinical 
studies have confirmed that lifestyle modification and drug treatment with 
metformin, acarbose, PPARγ agonist and orlistat can prevent progression to DM in 
30-60% of subjects with IGT or gestational diabetes, (Chiasson et al. 2004; Snitker 
et al. 2004; Heymsfield et al. 2000), our findings can be used to develop a strategy 
to select high risk women for surveillance and possible intervention. 
 
Studies have confirmed the link between insulin resistance during pregnancy and 
the development of gestational hypertension and pre-eclampsia, (Bryson et al. 2003; 
Emery et al. 2005; Carpenter 2007) which in turn are associated with future risk of 
hypertension and cardiovascular risk.  We have demonstrated that women with 
history of gestational diabetes who became AGT at 8 year post-delivery were 
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significantly more insulin resistant than women who were NGT at pregnancy and 
remained NGT at 8 years.  In addition, insulin sensitivity (as assessed by Matsuda-
ISI and QUICKI) at 8 years was independently predictive of the presence of type 2 
diabetes at 15 years after adjustment for gestational diabetic status, maternal age, 
BMI at the index pregnancy, and AGT status at 8-year post-delivery.  However, we 
did not find the same prediction with beta cell functions (represented by HOMA-
BCF and the insulinogenic indices).  Although it has been well accepted that the 
interplay between insulin resistance and decrease beta cell capacity pre-dates the 
occurrence of frank DM (Weyer et al. 1999; Tripathy et al. 2000; Kahn 2003; 
Kitabchi et al. 2005; Lyssenko et al. 2005; Abdul-Ghani et al. 2006; Xiang et al. 
2006; Cnop et al. 2007), Tabák and colleagues (2009) have recently demonstrated 
the beta cell function might not decline until at 2 years prior to the occurrence of 
DM.  It now becomes much clearer that insulin sensitivity already starts to decline 
as long as 13 years prior to the occurrence of DM while the trajectory of beta cell 
function could follow a rise between 3-4 years and decline by 2 years prior to DM 
(Tabák et al. 2009).  Our findings, hence, can demonstrate that insulin sensitivity 
indices based on Matsuda and QUICKI models are rather robust in predicting the 
progression to DM 7 years ahead in women with gestational diabetes in pregnancy, 
independent of AGT status at 8 years post-delivery. 
 
Our result also provided information to refine the high risk group at 8 years post-
delivery.  Detecting women who are insulin resistant though without progression to 
AGT at an intermediate follow up (8 years post-delivery) certainly can identify 
 61 
those at high risk of progression to DM at a longer follow up interval (15 years 
post-delivery).  
 
Finally, we have to acknowledge the several weakness of the study, namely, a 
rather small sample size of the cohort and unavoidable drop-out rate in a long term 
follow up study design.  This may account for the lack of predictability of beta-cell 
function at baseline on DM and of gestational diabetes on future MetS.  Moreover, 
detail history on dietary pattern and level of physical activity at the baseline was 
lacking.  Such information would be important as any lifestyle modification after 
the diagnosis of gestational diabetes and AGT will alter the predetermined course 






Our study result confirmed the first hypothesis.  In this 15 year prospective study, 
we had found in this unselected population with prior history of gestational 
diabetes, the conversion rate increased at an average rate of 1.6% per year.  A prior 
history of gestational diabetes increased in the risk progression to type 2 DM by 8-
fold as compared to the controls after adjustment of maternal age, overweight in 
early pregnancy and family history of DM. The increasing awareness on the risk of 
type 2 DM after gestational diabetes, the implication of insulin resistance at some 
years after the pregnancy, could help us to refine a woman’s future diabetic risk 
and provide us an opportunity to follow up and offer dietary, lifestyle and 
pharmacological interventions to prevent or delay the onset of type 2 DM in these 
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GLYCAEMIC VARIABLES MEASURED AT MID-GESTATION OF THE INDEX 
PREGNANCY PREDICT WOMEN’S FUTURE CARDIOMETABOLIC RISK 
 
This chapter will focus on the prediction of women’s long term cardiometabolic 
risk by using different glycaemic variables as well as their optimal cut-off threshold. 
Hypothesis 2:  
Glycaemic indices measured at mid-gestation of the index pregnancy predict 
women’s future cardiometabolic risk. 
 
4.1 Glycaemic levels in pregnancy and perinatal outcome 
 
There is substantial evidence that the traditional criteria for diagnosis of gestational 
diabetes are arbitrary.  Historically, this was predominantly based on the prediction 
of DM postpartum in women with relative hyperglycaemia during pregnancy. The 
very first O’Sullivan criteria was established arbitrarily using glucose levels at 2 
standard deviations above the mean threshold in a pregnant population as described 
in Chapter 1 (O'Sullivan & Mahan 1964).  However, neither the criteria modified 
from O’Sullivan nor the World Health Organization (WHO) criteria was based 
specifically on the perinatal outcomes. 
 
There has been a long argument about the relationship between maternal 
hyperglycaemia during pregnancy and adverse pregnancy outcome; as well as what 
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criteria should ideally identify pregnancies at risk of complications (Berkus & 
Langer 1993; Jensen, et al. 2001; Dorte et al., 2008; Moses & Calvert 1995; Sermer 
et al. 1995).  This point has been finally addressed by recent HAPO study result 
demonstrating a graded association between less severe degree of maternal 
hyperglycaemia below the current standard diagnostic criteria and a number of 
adverse pregnancy outcomes (HAPO 2008).  A new diagnostic criteria for the 
diagnosis of gestational diabetes mellitus was proposed by the IADPSG consensus 
panel on the basis of the HAPO study result (IADPSG consensus panel 2010).  
Ever since then, there has been much discussion and debates on the adoption of this 
new diagnostic criteria (Leary et al. 2010; Blackwell 2011; Rouse 2011).  Some 
accept and favour for such approach (Agarwal et al. 2011; Chevalier et al. 2011; 
Wilson 2011), whilst others concern the impact on an increasing workload (Flack 
et al. 2010, Morikawa et al. 2010).  The discussion on the new diagnostic criteria is 
ongoing and consensus meetings are going to be held by both the National Institute 
of Health and WHO by the end of 2012. 
 
4.2 Glycaemic levels in pregnancy and women’s future cardiometabolic 
risk 
 
Based on the study from the original cohort, we have previously demonstrated that 
a lower glucose levels than currently used for GCT gave a better prediction of 
gestational diabetes diagnosed on the basis of WHO criteria in our Chinese 
population (Tam et al. 2000).  Moreover, studies also demonstrated that children 
born to mothers without gestational diabetes but with an abnormal GCT also had a 
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gradual increase in the rate of macrosomia, large-for-gestational age and caesarean 
section in relation to increasing GCT severity categories (Lapolla et al. 2007; 
Yogev et al. 2005). 
 
It, therefore, raises the question that whether the glucose levels at GCT and at the 
OGTT currently used for the screening and diagnosis of gestational diabetes are the 
optimal threshold in the prediction of future DM and other cardio-metabolic risk. 
 
4.2.1 Prediction of women’s cardiometabolic risk at 8 and 15-year 
 
Table 4.1 showed the AUC-ROC of all the glycaemic indices in the prediction of 
women’s risk of AGT, DM, hypertension and MetS at 8 year.  With the exception 
of FPG in the prediction of hypertension, all glycaemic indices were significantly 
predictive of AGT, DM and hypertension.  GCT showed moderate prediction on 
mothers’ future risk of DM at the 8-year follow up (AUC-ROC = 0.81).  However, 
none of the glycaemic indices were predictive of women’s future MetS (all p 
values > 0.05). 
 
Table 4.2 showed the AUC-ROC of all the glycaemic indices in the prediction of 
women’s risk of AGT, DM, hypertension and MetS at 15 year.  With the exception 
of FPG in the prediction of hypertension, all glycaemic indices were predictive of 
AGT, DM and hypertension.  GCT also showed a good prediction on mothers’ 
future risk of DM at the 15-year follow up (AUC-ROC = 0.84).  FPG but not the 
other two indices, was found to be predictive of development of MetS at 15-year. 
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Table 4.1 Prediction of women's risk on abnormal glucose tolerance (AGT), DM, hypertension and metabolic syndrome (MetS) at 8 
years after delivery using glycaemic indices during pregnancy 
 
 





 AUC of ROC 
curves (95% CI) 
p AUC of ROC 
curves (95% CI) 
p AUC of ROC 
curves (95% CI) 
p AUC of ROC 
curves (95% CI) 
p
           
GCT 6.9 (1.7)  0.72 (0.63–0.80) <0.001 0.81 (0.67–0.95) 0.002 0.65 (0.52–0.76) 0.02 0.53 (0.41–0.66) 0.66 
FPG 4.1 (0.5)  0.62 (0.53–0.71) 0.012 0.75 (0.60–0.89) 0.013 0.58 (0.46–0.71) 0.19 0.56 (0.43–0.69) 0.43 
2-h PG 6.8 (1.8)  0.69 (0.60–0.77) <0.001 0.70 (0.49–0.91) 0.044 0.64 (0.52–0.76) 0.03 0.50 (0.38–0.63) 0.97 
           
 
2-h PG, second hour plasma glucose; AUC, area under curve; CI, confidence interval; FPG, fasting plasma glucose; GCT, glucose challenge test; ROC, receiver operating characteristic 




Table 4.2 Prediction of women's risk on abnormal glucose tolerance (AGT), DM, hypertension and metabolic syndrome (MetS) at 15 
years after delivery using glycaemic indices during pregnancy 
 
 





 AUC of ROC 
curves (95% CI) 
p AUC of ROC 
curves (95% CI) 
p AUC of ROC 
curves (95% CI) 
p AUC of ROC 
curves (95% CI) 
p 
           
GCT 6.8 (1.8)  0.75 (0.66–0.84) <0.001 0.84 (0.76–0.92) <0.001 0.67 (0.58–0.77) 0.003 0.63 (0.51–0.74) 0.054 
FPG 4.1 (0.6)  0.70 (0.61– 0.81) <0.001 0.74 (0.61–0.86) 0.002 0.61 (0.49–0.73) 0.053 0.65 (0.54–0.76) 0.022 
2-h PG 6.8 (1.9)  0.72 (0.63–0.81) <0.001 0.76 (0.66–0.87) 0.001 0.70 (0.61–0.80) 0.001 0.62 (0.51–0.73) 0.063 
           
 
2-h PG, second hour plasma glucose; AUC, area under curve; CI, confidence interval; FPG, fasting plasma glucose; GCT, glucose challenge test; MPG, mean plasma glucose; 
ROC, receiver operating characteristic analysis; SD, standard deviation 
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The comparison of the performance of individual glycaemic indices in the 
prediction of AGT, DM, hypertension and MetS using Delong paired test did not 
show any significant difference. 
 
4.2.2. Optimal cut-off levels in predicting women’s future cardiometabolic risk 
 
Optimal level of each glycaemic index was determined by the maximal Youden 
index based on the prediction of DM at 15 years. 
 
Table 4.3 showed the sensitivity, specificity and Youden indices at the glycaemic 
levels at and next to the optimal threshold in the prediction of women’s DM at 15 
years after the index pregnancy.  Optimal thresholds were 4.2, 7.2 and 7.7 mmol/L 
for FPG, 2-h PG and GCT respectively.  The optimal cut-off points were also 
shown in the ROC curves in Figure 4.1 
 
The optimal thresholds of various glycaemic indices above were then used to 
assess the women’s relative risks of AGT, DM and hypertension at both 8 and 15 
years.  Table 4.4 showed the relative risks at 8 and 15 years.  Mothers’ who had 
GCT ≥7.7 mmol/L had a relative risk of 15 and 14 in the conversion to type 2 DM 
at 8 and 15 years after pregnancy respectively.  Likewise, 2-h PG at OGTT ≥ 
7.2 mmol/L gave relative risks of 5.3 and 4.9 at 8 and 15 years respectively. Both 




Table 4.3 Sensitivity, specificity and Youden indices at the glycaemic levels at and 
next to the optimal threshold of the various glycaemic indices during pregnancy in 
the prediction of DM at 15 years post-delivery 
 
 
Glycaemic index Glucose level 
(mmol/L) 
Sensitivity Specificity Youden 
index 
     
GCT 
7.6 0.88 0.73 0.60 
7.7 0.88 0.74 0.61 
7.8 0.82 0.74 0.56 
    
2-h PG 
7.1 0.75 0.64 0.39 
7.2 0.75 0.67 0.42 
7.3 0.69 0.68 0.37 
    
FPG 
4.1 0.81 0.54 0.35 
4.2 0.75 0.62 0.37 
4.3 0.63 0.72 0.35 
 




Figure 4.1 Receiver operating characteristic curves in predicting women's risk of 


























After adjusting for the maternal age, BMI at booking, family history of DM, 
gestational hypertension, pre-eclampsia during the index pregnancy and number of 
subsequent deliveries, most of the glycaemic indices were not predictive of 
hypertension, except 2-h PG for the prediction of hypertension at 15 years (Table 
4.4). 
 
Table 4.5 showed the absolute risks AGT, DM and hypertension at 8 and 15 years 
at a glycaemic levels at or above the optimal threshold of each glycaemic index.  
Mothers who had 2-h PG at OGTT ≥ 7.2 mmol/L had 8.6% and 22.6% of risks in 
the conversion to type 2 DM at 8 and 15 years after pregnancy respectively.  
Similarly, mothers who had GCT ≥ 7.7 mmol/L had 11.6% and 30.4% of risks in 




Table 4.4 The relative risks of abnormal glucose tolerance (AGT), DM, hypertension at 8 and 15 years after delivery using various 
glycaemic indices during pregnancy 
 
Glycaemic indices at optimal 
threshold in the prediction of 
DM at 15 year 
Relative risks (95% CI) at 8 year Relative risks (95% CI) at 15 year 
AGT DM Hypertension 
 
AGT DM Hypertension 
         
 
FPG ≥ 4.2 mmol/L 
 
1.7 (1.1–2.7) 4.5 (0.95–21) 1.3 (0.5–2.8)  2.0 (1.2–3.3) 4.1 (1.4–12) 1.9 (1.0–3.5) 
2.0 (1.0–4.0)* 5.0 (0.97–25)* 1.3 (0.5–3.5)‡  3.2 (1.4–7.1)* 5.5 (1.6–20)* 2.2 (0.9–5.6)‡
     
 
2–h PG ≥ 7.2 mmol/L 
 
2.2 (1.3–3.5) 5.3 (1.1–25) 2.6 (1.1–5.9)  2.5 (1.5–4.0) 4.9 (1.7–14) 3.0 (1.5–5.7)
2.6 (1.3–5.2)* 6.1 (1.2–32)* 2.0 (0.7–5.5)‡  5.6 (2.4–13)* 5.9 (1.7–21)* 4.2 (1.6–11)‡ 
     
 
GCT ≥ 7.7 mmol/L 
 
3.2 (2.0–5.2) 15 (1.9–118) 2.7 (1.2–6.0)  3.1 (1.8–5.2) 14 (3.3–58) 1.9 (1.0–3.4)
4.2 (2.0–8.6)* 16 (1.9–138)* 1.5 (0.5–4.3)‡  5.4 (2.3–13)* 16 (3.2–82)* 1.4 (0.6–3.5)‡ 
     
 
2-h PG, second hour plasma glucose; CI, confidence interval; FPG, fasting plasma glucose; GCT, glucose challenge test 
*Adjustment for maternal age, BMI at booking, family history of DM during the index pregnancy and number of subsequent pregnancies. 




Table 4.5 The absolute risks of abnormal glucose tolerance (AGT), DM, hypertension at 8 and 15 years after delivery using various 
glycaemic indices during pregnancy 
 
 
Glycaemic indices at optimal 
threshold in the prediction of 
DM at 15 year 
Absolute risks at 8 years Absolute risks at 15 years 
AGT DM Hypertension  AGT DM Hypertension 
         
 
FPG ≥ 4.2 mmol/L 
     
32.6 7.9 12.2  42.4 20.3 30.5 
     
 
2-h PG ≥ 7.2 mmol/L 
     
37.0 8.6 17.1  50.0 22.6 37.7 
     
 
GCT ≥ 7.7 mmol/L 
     
46.4 11.6 18.6  54.3 30.4 32.6 
     
 





Among the 3 glycaemic indices studied at the index pregnancy, GCT appears a good 
predictor of women’s progression to DM in their later life. GCT at the optimal level 
achieves a sensitivity of 0.88 and specificity of 0.74 on the prediction of DM at 15 
years. 
 
The results suggested that a threshold of GCT and OGTT glucose levels lower than the 
current screening and diagnostic criteria respectively were predictive of a woman’s 
progression to AGT, DM and hypertension at both 8 and 15 years after pregnancy.  
The optimal thresholds for FPG, 2-hPG and GCT were 4.2, 7.2 and 7.7 mmol/L 
respectively. Women’s long term risk of DM was increased by about 16-fold at both 8 
and 15 years when the GCT was ≥7.7 mmol/L.  The long term risk of DM was 
increased by about 6-fold when the 2-h PG was ≥7.2 mmol/L. 
 
In a recent study on a large cohort of women who had undergone both GCT and 
OGTT, Carr et al. (2008) demonstrated a graded increase in the risk of future DM 
across all GCT quartiles.  The adjusted hazard ratio was 3.6 when the mother’s GCT at 
the highest quartile (≥ 7.4 mmol/L) as compared to the lowest quartile (≤ 5.3 mmol/L) 
at a median follow up of 8.8 years (Carr et al. 2008). Studies have shown that 1-hour 
glucose levels of the OGTT were predictor of immediate postpartum insulin resistance 
and type 2 DM at 5 years after pregnancy (Dalfra et al. 2001; Shah et al. 2008).  
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Unfortunately, the 1-hour glucose level of the 75 gram OGTT during the index 
pregnancy, which is included in the new diagnostic criteria (IADPSG 2010), was not 
available in our cohort for such risk prediction.  Other antenatal predictors of type 2 
DM were pre-pregnant BMI, gestational week of diagnosis, persistent fasting and 
postprandial hyperglycaemia requiring insulin therapy were significant antenatal 
predictors (Dalfra et al. 2001; Cheung & Helmink 2006; Baptiste-Roberts et al. 2009).  
However, no previous studies have addressed to the optimal threshold of GCT and 
OGTT in the prediction of future DM and other cardio-metabolic risk.  In this original 
cohort study which gestational diabetes was screened by universal OGTT in an 
unselected population, no woman actually required insulin treatment during the index 
pregnancy. 
 
Large epidemiological studies have demonstrated a high prevalence of DM in young 
Chinese as well as an increase in undiagnosed pre-diabetes and diabetes (Ko et al. 
1999b; Wong & Wang 2006).  The present study has, therefore, provided some useful 
information on how the various glycaemic indices at mid-gestation in a cohort of 
relatively young women at a mean age of 28 years on the long term prediction of both 
pre-diabetics and type 2 DM. 
 
In Chapter 3, a prior history of gestational diabetes was not found to increase the 
women’s long term risk of MetS.  Similarly, the various glycaemic indices during 
pregnancy were not found to be predictive of MetS at 8 and 15 years after delivery.  
This is on the contrary to the several follow up studies on women with prior history of 
gestational diabetes had demonstrated an increased risk of MetS, which in turn 
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associated with cardiovascular risk (Albareda et al. 2005; Cabre et al. 2008; Ford 2005; 
Holewijn et al. 2009; Lauenborg et al. 2005; Wender-Ozegowska et al. 2007). Our 
study could have been limited by the relative small sample size and modest attrition 
rate.  Moreover, our result may not be generalizable to other ethnic groups.  Therefore, 
further large multi-ethnic studies are needed to confirm this observation and to refine 
the optimal thresholds. 
 
Several HAPO study field centres have already started the follow up study on HAPO 
study participants and their children.  Furthermore, National Institute of Diabetes, 
Digestive and Kidney Diseases also approved a funding to the HAPO study which will 





In this long term follow up study, we have demonstrated that GCT at mid-gestation of 
pregnancy is a good predictor, whereas FPG and 2-h PG in the OGTT were moderate 
in the prediction of DM at both 8 and 15 years post-delivery.  The results supported 
Hypothesis 2. 
 
The optimal thresholds of GCT and glycaemic levels in the OGTT in predicting 
women’s future cardiometabolic risk in our Chinese population were found to be lower 
than that of the current criteria.  While the diagnostic criteria for gestational diabetes 
has been proposed and under consideration, further study to address the optimal 
glycaemic threshold which best predict a woman’s long term cardiometabolic risk, in 
particular the risk of DM would be worthwhile.  
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MATERNAL GESTATIONAL DIABETES AND OFFSPRING’S CARDIOMETABOLIC RISK 
 
This chapter gives an account on how maternal gestational diabetes affects the 
children’s long term cardiometabolic risk. 
Hypothesis 3:  
Maternal gestational diabetes increases the children offspring’s cardiometabolic risk 
 
5.1 Offspring’s cardiometabolic risk at 8 years age 
 
A total of 164 children offspring (101 of mothers with NGT; 63 of mothers with 
gestational diabetes of whom 7 were treated with diet during the index pregnancy 
according to our previous treatment criteria) completed both the physical examination 
and the biochemical blood assay at the 8 year follow up assessment. 
 
5.1.1 Baseline characteristics at pregnancy and delivery 
 
Table 5.1 shows the maternal characteristics, obstetric outcomes and cord blood C-
peptide and insulin levels between offspring of mothers with NGT and those of 
mothers with gestational diabetes.  The fasting and 2-h PG levels of 75 gram OGTT at 
pregnancy were significantly higher among mothers with gestational diabetes.  
Moreover, a higher proportion of infant of mothers with gestational diabetes were 





Table 5.1 Mothers’ clinical parameters at the index pregnancy stratified by their gestational 
diabetic status 
 
 NGT (n = 101) 
Gestational 
diabetes 
(n = 63) 
p§ 
Maternal characteristics & obstetric data:  
75 gram OGTT, fasting PG (mmol/L) 4.0 (0.4) 4.4 (0.6) <0.001
75 gram OGTT, 2-h PG (mmol/L) 5.8 (1.0) 8.2 (1.3) <0.001
Maternal age at delivery (years) 28.0 (4.2) 28.5 (4.0) 0.064
Caesarean delivery 10 (9.9) 21 (33.3) <0.001
Neonatal outcome:    
Gestational age at delivery (weeks) 39.5 (1.6) 39.3 (2.1) 0.81
Male: female 55: 46 (54.5:45.5) 26: 37 (41.2:58.8) 0.10
Neonatal birth weight (g) 3245 (429) 3292 (485) 0.50
Umbilical cord C-peptide level (nmol/ml) 0.62 (0.49) 0.70 (0.42) 0.33
Umbilical cord insulin level (pmol/l) 49.9 (50.5) 61.6 (54.6) 0.26
 
Data was expressed in either mean (SD) or number (%) 
§p-values comparing those with NGT and gestational diabetes by using the Student’s t-test, Chi-square 
where appropriate; 
NGT, normal glucose tolerance; PG, plasma glucose; OGTT, oral glucose tolerance test. 
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5.1.2 Children’s clinical and biochemical parameters at 8 years age 
 
Table 5.2 shows the children’s clinical and biochemical parameters at 8 years age 
stratified by mother’s gestational diabetic status.  Children offspring of mothers with 
gestational diabetes were slightly younger than those of mothers with NGT at the 
follow up (7.7 years vs. 8.4 years; p<0.001).  In view that the anthropometric indices 
and biochemical parameters could vary with age and gender, all the continuous 
variables were compared after adjustment for the child’s age and gender. 
 
Children of mothers with gestational diabetes were found to have significantly higher 
systolic (94 ± 1.2 mmHg vs. 88 ± 0.9 mmHg, p<0.001) and diastolic (62 ± 0.8 mmHg 
vs. 57 ± 0.6 mmHg, p<0.001) BPs and lower HDL-C levels (1.58 ± 0.04 mmol/L vs. 
1.71 ± 0.03 mmol/L, p = 0.019) than children of NGT mothers after adjustment (Table 
5.2). 
 
A total of 6 children had an abnormal OGTT results (5 IGR and 1 DM). There was no 
significant difference in the prevalence of AGT, insulin resistance, beta cell function, 




Table 5.2 Children’s clinical parameters at 8 years of age stratified by maternal 
gestational diabetic status 
 
NGT 
(n = 101) 
Gestational diabetes 
(n = 63) p 
Parental glycaemic status at 8 year follow up:    
Maternal glycaemic status at follow up 
IGR 13 (12.9) 18 (29) 
0.002 
DM 2 (2) 6 (9.7) 
Paternal history of DM 4 (4.0) 1 (1.6) 0.35 
Children’s characteristics at 8 year follow up:    
Age  8.4 (0.9) 7.7 (0.8) <0.001 
Body weight (kg)* 28.2 (0.7) 28.1 (0.9) 0.92 
Waist circumference (cm)* 56.1(0.7) 56.9 (0.9) 0.51 
Percentage of body fat (%)* 14.6 (0.8) 16.8 (1.1) 0.12 
Body mass index (BMI) (kg/m2)* 16.2 (0.3) 16.2 (0.4) 0.86 
Obesity 
WC 85th percentile 24 (23.3) 14 (22.2) 0.87 
BMI ≥ 85th percentile 26 (25.5) 19 (30.2) 0.51 
Systolic BP (mmHg)* 88 (0.9) 94 (1.2) <0.001 
Diastolic BP (mmHg)* 57 (0.6) 62 (0.8) <0.001 
75 gram OGTT, fasting PG (mmol/L)* 4.7 (0.04) 4.7 (0.06) 0.78 
75 gram OGTT, 2-h PG (mmol/L)* 5.2 (0.09) 5.4 (0.12) 0.29 
Fasting insulin level (pmol/L)* 64.7 (5.1) 66.4 (6.6) 0.84 
Children’s glycaemic status 
IFG 2 (2) 1 (1.6) 
0.86 IGT 1 (1) 1 (1.6) 
DM 1 (1) 0 
HDL-C (mmol/L)* 1.71 (0.03) 1.58 (0.04) 0.019 
LDL-C (mmol/L)* 2.5 (0.08) 2.7 (0.1) 0.08 
Triglyceride (mmol/L)* 0.92 (0.04) 0.83 (0.06) 0.27 
Total cholesterol (mmol/L)* 4.6 (0.08) 4.7 (0.1) 0.62 
Insulin sensitivity indices  
HOMA-IR* 2.0 (0.2) 2.1 (0.2) 0.82 
Matsuda-ISI* 7.7 (0.4) 7.1 (0.5) 0.35 
QUICKI* 0.36 (0.004) 0.36 (0.005) 0.60 
Βeta cell function HOMA-BCF* 140 (13.2) 162 (17.0) 0.33 
Disposition index* 816 (97) 832(125) 0.92 
 
Data was expressed in either mean (SD) [for age] or number (%) as appropriate;  
*Data was expressed in adjusted mean (SEM) controlling for the child’s age and gender 
 
BMI, body mass index; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; HDL-C, high-density 
cholesterol; HOMA-BCF, homeostasis model assessment of beta cell function; HOMA-IR, Homeostasis model 
assessment insulin resistance index; LDL-C, low-density lipoprotein cholesterol;Matsuda-ISI, Matsuda insulin 
sensitivity index; QUICKI, quantitative insulin sensitivity check index; WC, waist circumference 
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5.2 Offspring’s cardiometabolic risk at 15 years age 
 
A total of 129 adolescent offspring (87 mothers with NGT and 42 mothers with 
gestational diabetes, of whom 6 were treated with diet during the index pregnancy 
according to our previous treatment criteria) completed both the physical examination 
and the biochemical blood assay at 15 years of age.  A total of 14 adolescent children 
were diagnosed AGT (1 DM, 12 IGT and 1 IFG). 
 
5.2.1 Adolescents’ clinical and biochemical parameters at 15 years age 
 
Table 5.3 shows the adolescents’ clinical and biochemical parameters at 15 years age 
between the 2 groups.  There were no statistical differences in the age of follow up, 
Tanner stage, anthropometric parameters, blood pressures, plasma lipid levels and the 
rate of AGT between the adolescent children of mothers with NGT and of mothers 
with gestational diabetes. 
 
5.2.2 Clinical parameters of adolescents with AGT 
 
When adolescents with AGT were compared with those with NGT (Table 5.4), they 
were significantly more obese and had greater adiposity than those with NGT as 
reflected by being heavier (62.7 ± 15.5 kg vs. 55.4 ± 11.7 kg; p = 0.04), higher BMI 
(23.1 ± 4.4 kg/m2 vs. 20.8 ± 3.7 kg/m2; p = 0.03), WC (79.6 ± 11.1 cm vs. 72.8 ± 9.7 
cm; p = 0.02)  and  percentage  of  body  fat  (27.4  7.3% vs. 22.6  7.3%; p = 0.02). 
  
 85 
Table 5.3 Demographic characteristics, cardiometabolic status of the offspring of 
mothers with NGT and gestational diabetes after 15years follow up 
 
NGT 
(n = 87) 
Gestational diabetes 
(n = 42) p 
    
Age 14.8 (0.8) 15.0 (0.8) 0.25 
Male: Female 46: 41 (53:47) 19: 23 (47:53) 0.42 
Body weight (kg) 55.7 (12.5)  56.8 (12.0) 0.65 
Tanner stage (interquartile range) 4 (3–4) 4 (3–4) 0.45 
Body height (cm) 163.3 (7.6) 162.7 (8.6) 0.68 
Waist circumference (cm) 73.3 (10.1) 73.8 (9.9) 0.81 
Hip circumference (cm) 93.7 (8.2) 95.1 (7.4) 0.35 
Waist-Hip ratio 0.78 (0.05) 0.77 (0.06) 0.55 
Percentage of body fat (%) 22.5 (7.4) 24.4 (7.2) 0.17 
Body mass index (BMI) (kg/m2) 20.8 (3.8) 21.4 (3.7) 0.40 
Average weight gain since 8 year 
assessment (kg/year)  3.91 (1.22) 4.16 (1.32) 0.30 
Average weight gain since birth (kg/year) 3.55 (0.81) 3.59 (0.86) 0.80 
Peripheral SBP (mmHg) 111 (10) 113 (10) 0.46 
Peripheral DBP (mmHg) 66 (8) 68 (7) 0.46 
Fasting glucose (mmol/L) 4.7 (0.3) 4.6 (0.3) 0.51 
Second hour glucose (mmol/L) 5.6 (1.4) 6.0 (1.5) 0.16 
HDL-C level (mmol/L) 1.4 (0.3) 1.4 (0.2) 0.95 
LDL-C level (mmol/L) 2.0 (0.6) 2.1 (0.5) 0.34 
Total cholesterol (mmol/L) 3.9 (0.6) 3.9 (0.6) 0.84 
Triglyceride (mmol/L) 1.0 (0.4) 0.9 (0.5) 0.48 
Glycaemic status 
IFG 1 (1.1%) 0 
0.77* IGT 8 (9.2%) 4 (9.8%) 
DM 0 1 (2.4%) 
HDL < 1.03 mmol/L 3 (3.4%) 2 (4.8%) 0.72 
Fasting PG ≥ 5.6 mmol/L or AGT 9 (10.3%) 5 (11.9%) 0.79 
Triglyceride ≥ 1.7 mmol/L 6 (6.9%) 4 (9.5%) 0.60 
Waist circumference ≥ 90th percentile† 29 (33.3%) 17 (40.5%) 0.43 
BP ≥ 90th percentile† 8 (9.2) 4 (9.5) 0.95 
Metabolic syndrome 3 (3.4%) 3 (7.1%) 0.35 
    
Data was expressed in either mean (SD) or number (%) unless specified. 
* p value calculated based on rate of abnormal glucose tolerance (include IFG, IGT or DM) 
†According to the age-sex specific reference range in the Hong Kong Chinese population  
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Table 5.4 Demographic characteristics, cardiometabolic status of adolescents who have 
normal glucose tolerance (NGT) and abnormal glucose tolerance (AGT) at the 15-year 
follow up 
 
 Children glycaemic status 
p 
 NGT (n = 114) AGT (n = 14) 
    
Age 14.9 (0.8) 14.7 (0.8) 0.45 
Male: Female 58:66 (51:49) 7:7 (50:50) 1.00 
Birth weight (g) 3262 (418) 3321 (461) 0.62 
Body weight (kg) 55.4 (11.7) 62.7 (15.5) 0.04 
Body height (cm) 163.0 (8.0) 164.3 (6.8) 0.58 
BMI (kg/m2) 20.8 (3.7) 23.1 (4.4) 0.03 
Total weight gain after birth (kg) 52.3 (11.6) 59.4 (15.5) 0.042 
Average weight gain since birth 
(kg/year) 3.51 (0.78) 4.04 (1.04) 0.024 
Waist circumference (cm) 72.8 (9.7) 79.6 (11.1) 0.02 
Hip circumference (cm) 93.7 (7.8) 98.8 (8.2) 0.03 
Waist-Hip ratio 0.78 (0.05) 0.80 (0.06) 0.07 
Percentage of body fat (%) 22.6 (7.3) 27.4 (7.3) 0.02 
Tanner stage(interquartile range) 4 (3–4) 3 (3–4.25)  0.17 
Peripheral SBP (mmHg) 111 (9.6) 116 (9.6) 0.11 
Peripheral DBP (mmHg) 66 (7.5) 70 (7.8) 0.09 
HDL-C (mmol/L) 1.39 (0.25) 1.37 (0.28) 0.80 
LDL-C (mmol/L) 2.05 (0.54) 2.12 (0.64) 0.62 
Triglyceride (mmol/L) 0.94 (0.45) 1.12 (0.58) 0.18 
Total cholesterol (mmol/L) 3.87 (0.61) 4.01 (0.62) 0.42 
†Waist circumference ≥ 90th centile 37 (32.5%) 9 (64.3%) 0.019 
†BP ≥ 90th percentile 8 (7.0) 4 (28.6) 0.009 
HDL < 1.03 mmol/L 5 (4.4%) 0 (0%) - 
Total triglyceride ≥ 1.7 mmol/L 8 (7.0%) 2 (14.3%) 0.34 
Metabolic syndrome 2 (1.8) 4 (28.6) <0.0001 
Data was expressed in either mean (SD) or number (%) unless specified. 




Despite that there was no difference in their birth weight, adolescents who developed 
AGT also had a significant increase in weight gain since birth (59.4  15.5 kg vs. 52.3 
 11.6 kg; p = 0.042) 
 
Furthermore, adolescent offspring developed AGT has a higher rate of hypertension 
(defined as BP ≥ age- and gender-specific 90th percentile) (28.6% vs. 7.0 %; p = 0.019) 






In this first prospective controlled study examining the effects of maternal gestational 
diabetes on the children’s cardio-metabolic risk in a Chinese population, maternal 
gestational diabetes was associated with significantly increased BP and decreased 
HDL-C levels in the children at a median age of 8 years.  This result is similar to the 
findings of Bunt et al. (2005) who showed higher systolic BP and lower HDL-C levels 
for children born during a pregnancy with DM than children born before the mother 
developed DM. 
 
Recently, data from the Fels longitudinal study suggested a link between children’s BP 
as early as 5 years of age and the development of hypertension and MetS in adulthood 
(Sun et al. 2007).  This may indicate a link between maternal gestational diabetes and 
long-term risk of hypertension and MetS in adulthood.  However, we did not find an 
increase in either hypertension or MetS among the offspring of mothers with 
gestational diabetes when they were reassessed at 15 years age. 
 
The rate of AGT in our cohort of children (3.66%; 6 out of 164 children) at 8 years age 
was similar to that reported for obese children from mainland China (Fu et al. 2007).  
The rate was increased by almost 3-fold to 10.9% (14 out of 129 adolescents) at 15 
years of age in the cohort.  Silverman et al. (1995) has previously showed that 
although children of DM mothers had the same rate of AGT as the normal controls at 
the age below 10 years, there was a marked increase in prevalence of IGT increased 
from 5.4% at 5–9 year to 19.3% at 10–16 year age.  However, we did not observe a 
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significantly increase rate of AGT among the children offspring of mothers with 
gestational diabetes when they reach their adolescence. 
 
Nonetheless, we did observe that obesity and postnatal weight gain are associated with 
the development of AGT in the adolescence.  In a similar follow up study on children 
of mothers with gestational diabetes, Catalano et al. (2009) did not show a significant 
increase in cardiometabolic risk among the children offspring of mothers with 
gestational diabetes.  However, childhood obesity was associated with maternal 
obesity rather than maternal glucose during pregnancy (Catalano et al. 2009). 
 
This points out that there could be other factors which associated with maternal 
gestational diabetes and determines the offspring’s future cardiometabolic risk.  
Therefore, we also examined the role of the effect of in utero environment, namely 
hyperinsulinaemia, on the metabolism of the offspring and their future cardiometabolic 





The results in this study supported Hypothesis 3. Maternal gestational diabetes 
increases the offspring’s cardiometabolic risk at childhood, namely higher risk of 
hypertension and adverse lipid profile at early childhood. 
 
However, we can only demonstrate a transient effect occurred during the childhood 
but it does not persist during their adolescence.  The study could have been limited by 
the small sample size, antenatal treatment effect and that effect size of gestational 
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IN UTERO HYPERINSULINAEMIA AND OFFSPRING’S CARDIOMETABOLIC RISK 
 
This chapter describes the effect of in utero hyperinsulinaemia in maternal gestational 
diabetes on long term cardiometabolic risk of the children offspring. 
Hypothesis 4:  
In utero hyperinsulinaemia in maternal gestational diabetes increases the offspring’s 
cardiometabolic risk 
 
6.1 Umbilical cord blood insulin and C-peptide 
 
As described in Chapter 2, umbilical cord blood was collected at the time of delivery 
for the assay of insulin and C-peptide concentrations.  Amongst the 942 women who 
completed the original study, umbilical cord blood insulin and C-peptide levels were 
available in 787 and 803 cases respectively.  The missing cases were predominantly 
due to non-adherence to the study protocol and technical failure in collection of 
umbilical blood at delivery. 
 
6.1.1 Umbilical cord blood insulin and C-peptide concentrations in the original 
cohort 
 
In an earlier publication, Roach et al. (1995) reported that the median umbilical cord 
blood insulin levels [7.3 µmol/ml (range: 0.1–56.0 µmol/ml) vs. 6.0 µmol/ml (range: 
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0.1–83.5 µmol/ml), p = 0.008] and C-peptide levels [0.6 (range: 0.01-4.3) vs. 0.5 
(range: 0.01-2.5), p = 0.001] were significantly higher among the subjects with GIGT 
(but not treated according to the earlier treatment criteria) than subjects with NGT in 
the original cohort. 
 
Figure 6.1 showed frequency distribution of umbilical cord blood insulin and C-
peptide levels of the original cohort.  To ensure both levels were expressed in SI units 
in the thesis, insulin levels were converted from (µmol/ml) to the SI unit (pmol/L) by a 





Figure 6.1 Frequency distribution of umbilical cord blood insulin and C-peptide levels 
at delivery 


































6.1.2 Determination of in utero hyperinsulinaemia by umbilical cord blood insulin 
and C-peptide levels 
 
The Pedersen hypothesis states that fetal macrosomia in infants of diabetic mothers are 
related to chronic hyperinsulinaemia as a response to fetal hyperglycaemia (Pederson 
1954).  Since maternal pro-insulin and insulin do not cross the placenta, unless in the 
rare occasions with presence of insulin antibodies, we can assume that umbilical cord 
insulin was derived solely from fetal  cell secretion and hence an indicator of fetal 
response to maternal glycaemic status.  However, most of the insulin molecules are 
degraded by liver cells on the first pass to the hepatic circulation with a half life of 
only 4 to 6 minutes (Duckworth et al. 1998).  Moreover, the concentration of insulin in 
the plasma of umbilical cord has been shown to vary with the mode of delivery. 
Infants delivered by caesarean section had a significantly higher cord insulin levels 
than those delivered by vaginal delivery; there was also a higher levels with 
emergency than elective caesarean section although not reach statistical difference 
(Shields et al. 2007).  The inherent physiological variation in the insulin concentration 
could limit its precision as a marker of in utero hyperinsulinaemia.  On the other hand, 
umbilical cord C-peptide, being a by-product of proteolytic cleavage of pro-insulin in 
the pancreatic  cells, can serve as a surrogate marker of insulin secretion.  The use of 
C-peptide measurement as an indicator of hyperinsulinaemia may offer an advantage 
over the use of insulin as it is not bound by anti-insulin antibodies, is minimally 
extracted by the liver, and assays are not affected by the presence of pro-insulin. 
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We have chosen levels at or above 90th percentile of the reference range in the cohort 
to define in utero hyperinsulinaemia in our study [i.e. umbilical cord insulin level 
≥ 90th percentile (Ins90) and umbilical C-peptide level ≥ 90th percentile (Cpep90)].  
The corresponding levels for insulin and C-peptide were 107.6 pmol/L and 1.2 nmol/L 
respectively. 
 
Figure 6.2 showed the scatter plot between umbilical cord insulin and C-peptide levels 
among the children offspring who participated in the follow up study.  Umbilical cord 
blood insulin and C-peptide were available in 107 and 112 subjects for the analysis.  
There was a weak but statistically significant correlation between the 2 levels 
(R = 0.20, p = 0.02).  Ins90 and Cpep90 occurred in 13 and 16 subjects who 
participated in the follow up study. 
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Figure 6.2 Scatter plot between umbilical cord blood C-peptide and insulin levels 
among the children offspring who participated in the follow up study 





























6.2 The effect of in utero hyperinsulinaemia on children’s AGT at 8 years of age 
 
6.2.1 ROC analysis 
 
We used ROC analysis to assess the predictability of umbilical cord blood insulin and 
C-peptide on the children’s risk of AGT at 8 years of age.  Cord blood insulin level 
[AUC-ROC = 0.81 (95% CI: 0.59–1.0, p = 0.020)] but not C-peptide levels [AUC-
ROC = 0.51 (95% CI: 0.30–0.73, p = 0.51)] was found to be predictive of children’s 
AGT. 
 
Figure 6.3 shows the ROC curve for both the umbilical cord blood insulin and C-
peptide levels in predicting AGT at early childhood.  The sensitivity and specificity 
were 0.80 and 0.83 respectively at the point of inflection which represents a cutoff for 
cord blood insulin level of 92 pmol/L. 
 
6.2.2 Logistic regression analysis 
 
Multivariate logistic regression analysis was used to obtain adjusted odds ratios with 
95% confidence intervals, with forced entry of Ins90, maternal gestational diabetic 
status at the index pregnancy, macrosomia at birth, childhood obesity and mother’s 
glycaemic status at 8 year post-delivery as independent variables.  A stepwise 
algorithm (p = 0.10 for entry and p = 0.05 for removal) was used to select other 
variables.  Model fit was assessed using the Hosmer and Lemeshow Goodness-of-Fit 
test. A p value < 0.05 was considered significant. 
 99 
Table 6.1 showed the prediction of children’s abnormal AGT at 8 years of age by a 
multivariate logistic regression model.  A high umbilical cord blood insulin level 
(Ins90) was found to be an independent risk factor for AGT (odds ratio: 8.9; 95% CI: 
1.08–72.7), whereas macrosomia, child’s waist circumference of ≥85th percentile, 
maternal gestational diabetic status, and mother’s glycaemic status were not shown to 




Figure 6.3 Receiver operating characteristic curve in the prediction of abnormal 
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Table 6.1 Multivariate logistic regression analysis model for the prediction of abnormal glucose intolerance (AGT) in the offspring at 8 
years of age 
 
  AGT in offspring Odds ratio (95% CI) 
Cord blood insulin level  
<= 90 percentile 3 (3.1 %) 
8.9 (1.08–72.7) 
 > 90 percentile 2 (20 %)
Maternal gestational diabetes status  
 NGT 4 (4.0 %) 
0.36 (0.03–3.8) 
GDM/GIGT 2 (3.2%)
Macrosomia at birth 
 < 4 kg 5 (3.2 %) 
6.12 (0.21–182) 
  4 kg 1 (11.1%)
Children’s waist circumference at follow up 
≥ 85 percentile 5 (3.9 %) 
1.4 (0.14–14.3) 
< 85percentile 1 (2.7%)
Mothers’ glycaemic status at follow up 




NTG, normal glucose tolerance; GDM, gestational diabetes mellitus; GIGT, gestational impaired glucose tolerance; IGR, impaired glucose regulation 
(=impaired fasting glucose or impaired glucose tolerance); DM, diabetes mellitus 
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6.3 The effect of in utero hyperinsulinaemia on adolescents’ 
cardiometabolic risk at 15 years of age 
 
6.3.1 Logistic regression analysis 
 
Multivariate logistic regression analysis was used to obtain adjusted odds ratios of 
cord blood insulin and C-peptide levels for AGT with forced entry of subject’s age, 
gender, Tanner’s stage, birth weight, maternal gestational diabetic status and 
maternal DM at the time of follow up evaluation. 
 
MetS in the adolescent was defined as previously mentioned in Chapter 2.  
Overweight was defined at BMI ≥ 90th percentile age- and sex specific reference 
range of Chinese individuals (Ng et al. 2007).  Since Mets and overweight were 
based on age- and sex specific BP, WC and BMI percentile, age and gender were 
not placed into the logistic regression analysis for their prediction.  Adjusted odds 
ratios were obtained with forced entry of subject’s Tanner’s stage, birth weight, 
maternal gestational diabetic status and maternal BMI at the time of follow up 
evaluation.  Model fit was assessed using the Hosmer and Lemeshow Goodness-of-
Fit test. A p value < 0.05 was considered significant. 
 
Table 6.2 showed the prediction of children’s AGT, MetS and overweight at 15 
years of age by cord blood insulin & C-peptide level.  Both cord blood insulin and 
C-peptide levels were not found predictive of AGT at 15 years of age.  However 
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cord blood C-peptide level significantly predicts adolescent overweight [odds ratio: 
7.66 (95% CI: 1.32–44.5); p = 0.023]. 
 
Cpep90 but not Ins90 was found to increase the risk for MetS [odds ratio: 17.6 
(95% CI: 1.32-235); p = 0.03] after adjustment for birth weight, Tanner staging, 
maternal gestational diabetic status and maternal BMI at follow up evaluation.  
Both Ins90 [odds ratio: 7.66 (95% CI: 1.32–44.5); p = 0.023] and Cpep90 [odds 
ratio: 10.8 (95% CI: 1.69–69.2); p = 0.012] significantly increased the risk of 





Table 6.2 The prediction of adolescents’ abnormal glucose tolerance (AGT), metabolic syndrome and overweight at 15 years age by cord blood 
insulin & C-peptide level 
 Odds ratio (95% CI) 
AGT p 
Odds ratio (95% CI) 
Metabolic syndrome p 
Odds ratio (95% CI) 
Overweight p 
Cord insulin (per pmol/L) 
0.99 (0.98–1.01) 0.48 0.99 (0.96–1.02) 0.46 1.01 (1.00–1.02) 0.085
0.99 (0.98–1.01)* 0.46 0.99 (0.96–1.02)* 0.46 1.01 (1.00–1.02)* 0.086
0.99 (0.98–1.01)*∆ 0.55 0.99 (0.97–1.02)*† 0.53 1.01 (1.00–1.02)*‡ 0.16
Cord insulin ≥ 90th vs. <90th percentile 
# # 7.63 (1.74–33.3) 0.007
# # 7.49 (1.71–32.9)* 0.008
# # 7.66 (1.32–44.5)*‡ 0.023
       
Cord C-peptide (per nmol/L) 
1.41 (0.34–5.88) 0.64 2.13 (0.34–13.4) 0.42 3.40 (1.03–11.2) 0.045
1.40 (0.35–5.60)* 0.64 2.12 (0.34–13.2)* 0.42 3.41 (1.03–11.3)* 0.045
1.34 (0.28–6.48)*∆ 0.86 1.84 (0.31–10.9)*† 0.50 4.77 (1.12–20.3)*‡ 0.034
       
Cord C-peptide ≥ 90th vs. <90th percentile 
1.16 (0.13–10.7) 0.90 10.1 (1.23–83.5) 0.031 5.04 (1.15–22.0) 0.032
1.03 (0.11–9.59)* 0.98 10.1 (1.23–83.9)* 0.032 5.34 (1.20–23.8)* 0.028
1.41 (0.09–22.4)*∆ 0.81 17.6 (1.32–235)*† 0.030 10.8 (1.69–69.2)*‡ 0.012
       
* adjusted for maternal gestational diabetic status 
∆ adjusted for age, gender, Tanner staging, birth weight and maternal DM at follow up evaluation 
† adjusted for Tanner staging, birth weight, maternal BMI at follow up evaluation 
‡ adjusted for Tanner staging, birth weight, maternal BMI at follow up evaluation 




Although we did share a similar finding as previously reported by Whitaker et al. 
(1998) that prenatal exposure to mild gestational diabetes did not increase the risk 
of childhood obesity, we found that in utero hyperinsulinaemia being an 
independent predictor of offspring’s AGT, Mets and overweight at different 
childhood stages. 
 
At childhood, a high umbilical insulin level was found to increase the odds of 
childhood AGT by 19-fold.  At the adolescence, a high umbilical cord blood C-
peptide level was found increase MetS by 15-fold.  In utero hyperinsulinaemia, 
whether defined by either high umbilical cord blood insulin or high umbilical cord 
blood C-peptide levels, also increased the risk being overweight at adolescence by 
7-fold, independent of their own birth weight, maternal gestational diabetic status 
and mothers’ BMI at the time of follow up. 
 
Our result suggests that in utero hyperinsulinaemic environment, irrespective of the 
severity of maternal gestational diabetes, is associated with increased risk of being 
overweight and developing MetS among the offspring at their early adolescence.  
This is similar to the result demonstrated previously among offspring of pre-
gestational diabetic mothers (Metzger et al. 1990; Silverman et al. 1995).  In both 
studies, researchers consistently demonstrated that excessive in utero insulin 
secretion, measured in the amniotic fluid, was an independent predictor of 
childhood obesity and IGT at their adolescence (Metzger et al. 1990; Silverman et 
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al. 1995).  Offspring whose mothers had either pre-gestational DM or gestational 
diabetes were also found to have a higher frequency of IGT at both childhood and 
adolescence, the rate of IGT was much higher in those with in utero 
hyperinsulinaemia at the third trimester (Silverman et al. 1995; Plagemann et al. 
1997). 
 
In contrast to the findings from earlier study that the effect of maternal gestational 
diabetes on offspring’s insulin resistance and MetS in childhood appeared to limit 
to those born large-for-gestational age (Boney et al. 2005), our result showed that 
the effect of hyperinsulinaemia on MetS and obesity was independent of the 
offspring’s birth weight.  Furthermore, the effect in utero hyperinsulinaemia of 
adolescent MetS and obesity was still significant after controlling for maternal 
obesity and offspring’s own birth weight. 
 
In a study on a large cohort of multiethnic U.S. population, Hillier and co-workers 
(2007) demonstrated that increasing maternal hyperglycaemia in pregnancy is 
associated with an increased risk of childhood obesity at age 5-7 years after 
adjustment for birth weight and maternal weight.  This appears consistent with our 
study result that utero hyperinsulinaemia maternal as a result of maternal 
hyperglycaemia has a long term effect on childhood obesity independent of their 
birth weight.  Early onset childhood obesity has now become an important health 
consequence as many large population studies suggested its persistence towards 
adolescence and young adulthood (Guo et al. 1994; Guo et al. 2002; Nader et al. 
 107 
2006).  Furthermore, Li et al. (2005) also reported that MetS has occurred up to 
18% of overweight and 38% of obese Chinese children. 
 
Our study result also prompts us to raise the question whether the current 
diagnostic criteria for gestational diabetes could ideally distinguish those offspring 
of gestational diabetic mothers at risk of future cardiometabolic risk.  The major 
pitfall in the area of gestational diabetes is a lack of consensus and reliable 
diagnostic criteria.  The very original O’Sullivan criteria, 50 years ago, was based 
arbitrarily on the glucose levels at 2 standard deviations above the mean.  All the 
subsequently modified and existing criteria had not been validated against the 
pregnancy outcome or long term outcome of the offspring.  Until recently, the 
result of the first pregnancy outcome based HAPO study indicated that there a need 
to revise diagnostic criteria of gestational diabetes mellitus which could 
appropriately relate to adverse pregnancy outcomes (HAPO study group, 2008).  
Finally, a new diagnostic criteria was proposed by the International Association of 
Diabetes and Pregnancy Study Groups Consensus Panel based on the HAPO study 
result in March 2010 (IADPSG 2010).  The discussion on adopting a new 
diagnostic criteria is still ongoing. 
 
Likewise, the result of the present study should prompt us to reconsider whether 
the existing diagnostic criteria are still appropriate to relate to the degree of 
intrauterine hyperinsulinaemia and hence predicting the future cardiometabolic risk 
of offspring.  The next Chapter will summarise all the findings and discuss the 




The results in this study supported Hypothesis 4. In utero hyperinsulinaemia in 
maternal gestational diabetes increases the offspring’s cardiometabolic risk.  It is 
associated with 7-fold increase in adolescent overweight and 15-fold increase in 
MetS. 
 
However, the increase risk of AGT was only demonstrated at childhood but not 
persistent at adolescence.  Similar to that aforementioned in the previous Chapter, 
the study was limited by the small sample size and the study design.  This issue 
will be discussed in the next Chapter. 
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SUMMARY AND CONCLUSION 
 
7.1 Summary of the thesis 
 
The thesis described the work related to studies which followed up a cohort of 
mothers who had gestational diabetes and normal glucose tolerance at 8 and 15 
years post-delivery on their progression into DM and other cardiometabolic risk, as 
well as that for their children offspring. 
 
7.1.1 Women’s long term cardiometabolic risk after a pregnancy with gestational 
diabetes 
 
Type 2 DM occurs in 9% and 24.4% at 8-year and 15-year post-delivery 
respectively among women with gestational diabetes.  Women who had gestational 
diabetes, based on the 1999 WHO criteria, have 8-fold and 3-fold increases in the 
risk of type 2 DM and hypertension respectively at 15 years later.   
 
Based on the result of ROC analysis, GCT level at mid-gestation of pregnancy was 
found to be a good predictor in the prediction of women’s DM risk at both 8 and 15 
years post-delivery.  Optimal cut-off thresholds of GCT, fasting & 2-h PG of the 
OGTT were lower than that currently used for the screening and diagnostic criteria 
for gestational diabetes. 
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7.1.2 The long term cardiometabolic risk of children born to mothers who had 
gestational diabetes 
 
Children born to mothers who had gestational diabetes during pregnancy have 
higher blood pressure and adverse lipid profile at 8 years of age as compared to 
normal controls.  In utero hyperinsulinaemia was found to be independent predictor 
of offspring’s AGT at 8 years of age, as well as their Mets and overweight at 15 
years of age.  
 
7.1.3 New findings from the studies and their implications 
 
Although the long term progression to type 2 DM is known among women with 
history of gestational diabetes, this is the first long term follow up study ever in our 
Chinese population up till 15 years post-delivery.  At present, gestational diabetes 
is predominantly screened by epidemiological risk factors, such as advanced 
maternal age, maternal obesity, family history of DM, other obstetric risks etc., 
instead of universal OGTT.  Mothers who are diagnosed gestational diabetes in this 
way are more likely to share similar risk factors of type 2 DM. 
 
Our population is, therefore, more representative of what the women’s future 
cardiometabolic risk is like when universal OGTT during pregnancy is in place 
regardless of women’s epidemiological risk.  To the best of our knowledge, this 
cohort is by then the only one in which the diagnosis of gestational diabetes is 
established by a universal OGTT in a Chinese population. 
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Although women were recruited from a low risk population at the mean age of 28 
years at pregnancy during the early 90’s, the rate of DM was nearly 25% among 
mothers who had gestational diabetes, majority of them were GIGT.  Therefore, 
mothers whose gestational diabetes was diagnosed after screening with 
epidemiological risk factors would be expected to have a much higher DM risk.  It 
is not unexpected that previous data from our unit demonstrated that 13% of the 
mothers with gestational diabetes already developed DM at 6 weeks postpartum 
(Ko et al. 1999a).  In summary, our studies have illustrated that gestational diabetes 
as an independent risk factor for future hypertension and type 2 DM, and have 
provided more precise estimation on such risk at long term. 
 
Postnatal glucose testing and at regular intervals by OGTT are in general the 
common recommendation to screen women with gestational diabetes for future 
IGT and type 2 DM (Simmons et al. 2010; Kim 2010).  However, its uptake rate 
remained suboptimal and disappointing (Ferrara et al. 2009; Kwong et al. 2009).  
This observation is the same for our Chinese population highlighted by the fact that 
most of the women would have remained undiagnosed if they had not participated 
in our follow-up study (Tam et al. 2007).  Our results demonstrated that by adding 
a fasting insulin level to the glucose testing, we can apply a simple QUICKI model 
as an independent prediction on women’s long term risk of type 2 DM. 
 
Although limited by the small number of children subjects in the cohort, our study 
is the first one to report the association between high umbilical cord insulin, C 
peptide and children’s overweight and metabolic syndrome at adolescence.  The 
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result may infer that intrauterine hyperglycaemic environment leading to 
hyperinsulinaemia could have an effect on long term cardiometabolic risk to the 
offspring.  Therefore, future research should also focus on the role of antenatal 
treatment of gestational diabetes would reduce the children’s long term risk of IGT, 
obesity and metabolic syndrome. 
 
7.2 Strength and weakness of the follow up study 
 
7.2.1 Unique cohort from universal screening 
 
The study population was selected from a cohort of 1031 women who were 
recruited in the early 1990’s into a study aiming to define the optimal screening 
method and diagnostic criteria of gestational diabetes in Chinese.  All subjects 
underwent a universal OGTT and GCT at mid-gestation.  A comprehensive dataset 
on the mothers’ antenatal, intrapartum and postpartum parameters were available 
for our study. 
 
7.2.2 Study design 
 
The study was designed to assess all 134 mother-child pairs of the gestational 
diabetes group with another 268 mother-child pairs of the normal glucose tolerance 
group, matched for maternal age, instead of the follow up on the entire cohort.  Part 
of the reason was because of the limited funding at the commencement of the 
whole project.  The case-control study design is deemed appropriate to compare the 
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women’s long term cardiometabolic risk between the cases (gestational diabetes) 
and controls (normal glucose tolerance in pregnancy).  However, in the 
examination of the Hypothesis 2, the prediction of women’s long term 
cardiometabolic risk by the various glycaemic variables using the ROC curve 
would be better if the follow up study involved all subjects from the original cohort.  
This would then provide a full spectrum of the glycaemic levels in order to assess 
the prediction model.  Likewise, in the examination of the Hypothesis 4, the whole 
spectrum of umbilical cord blood insulin and C-peptide levels from the original 
cohort had not be examined in the prediction of the children’s cardiometabolic risk. 
 
7.2.3 Response rate and loss to follow up 
 
Although 402 mother-child pairs were eligible for the follow up study on the basis 
of the study design, only 203 mothers (response rate: 50%) and 164 children had 
completed the 8-year follow up assessment.  At the 15-year follow up assessment, 
another 64 mothers (16%) and 35 children (8%) were lost to the follow up. 
 
The Prince of Wales Hospital is a regional hospital which served the obstetric 
population in the North Eastern part of the New Territories of Hong Kong since the 
early 1980’s.  The geographical location is associated with mobility across the 
border.  Quite a large proportion of the non-responded eligible subjects were not 
contactable through their previous telephone number and address.  The response 
rate could have been improved if the follow up study was started sooner after the 
delivery; this could have increase the retention of the original cohort in the follow 
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up.  Furthermore, some mothers and children had declined the rather 
comprehensive and frequent blood sampling involved in the study.  In summary, 
the follow up study is limited by the relatively small sample size at 8-year and 
modest case attrition at 15-year. 
 
7.2.4 Treatment effect of gestational diabetes 
 
In the early 1990’s, the unit had used a diagnostic criteria based on a 50 gram 
OGTT instead of the WHO criteria for clinical management.  As a result, only 
some of the women who had been diagnosed gestational diabetes, of them majority 
were GIGT, were treated by dietary therapy as mentioned in the previous Chapters.  
The dietary treatment will reduce maternal hyperglycaemia and hence mininise the 
potential harmful effect on the fetus in gestational diabetes.  Therefore, the original 
cohort may not be the perfect model to examine the long term effect of maternal 
gestational diabetes on the children’s long term cardiometabolic risk. 
 
7.3 Issues on future research 
 
7.3.1 Follow up study on the HAPO cohort 
 
Our unit is one of the centres contributing to the International multicentre HAPO 
study as mentioned in Chapter 1 and 4.  Our centre had recruited 1760 Chinese 
pregnant women between 2001 and 2005.  All mothers underwent a 75 gram 
OGTT between 24 and 32 weeks gestation.  The clinicians were blinded to the 
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results as long as the FPG ≤ 5.8 mmol/L & 2-h PG ≤ 11.1 mmol/L.  The maternal 
serum C-peptide and HbA1c, cord serum C-peptide and early neonatal plasma 
glucose, pregnancy outcome and the neonatal anthropometric parameters are 
available for future study.  This is so far the largest cohort in a Chinese population 
who has been investigated for glycaemia during pregnancy but with OGTT results 
remained blinded up till this moment. This unique cohort is most ideal for a study 
of the effect of in-utero hyperglycaemia on the children’s future cardiometabolic 
risk.  
 
Our research team has commenced another follow up study on the children, who 
currently are at 6 years of age, for the assessment of their cardiometabolic risk 
since January 2009.  There were 2 major objectives in this recent study: 
 
i. To evaluate effect in-utero hyperglycaemia and in-utero hyperinsulinaemia 
on the cardiometabolic risk profile of offspring.  
ii. To assess whether antenatal treatment will reduce children’s long term 
cardiometabolic risk 
 
There were 267 HAPO subjects who fulfilled the criteria GDM according to our 
current unit criteria.  Their children were classified as “untreated GDM” children 
group because the OGTT result had been blinded and the mothers had not received 
any treatment antenatally.  The children of another cohort of mothers, who had not 
been recruited into the HAPO study but had been diagnosed gestational diabetes by 
routine OGTT and been treated with dietary and insulin intervention, were 
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recruited as “treated GDM” children for comparison.  Both groups were matched in 
their age at assessment and their mothers’ degree of hyperglycaemia.  This study 
was funded by the Research Grant Council of Hong Kong at 2008.  Similarly, this 
potential effect of antenatal treatment on the children’s long term cardiometabolic 
risk could also be addressed from the follow up of subjects from the 2 multicentre 
randomised controlled trials on antenatal treatment to mild GDM (Crowther et al. 
2005; Landon et al. 2009). 
 
7.3.2 Opportunity for international collaboration 
 
Our research team has been in connection with the Steering Committee of the 
HAPO Study Cooperative Research Group.  Some other HAPO study centres had 
also started a follow up study on their own children cohort.  There has been an 
extension in the funding by the National Institute of Child Health and Human 
Development (NICHD) and the National Institute of Diabetes, Digestive, and 
Kidney Diseases, to explore the possibility of following up all the children from 
various study centres.  There have been meetings to discuss on sharing a common 






The thesis has described the first prospective long-term follow up study on Chinese 
women who had been diagnosed gestational diabetes on their long term 
cardiometabolic risk as well as that of their offspring.  Based on this research 
experience and the establishment of the infrastructure, our research team has 
proceeded to further follow up project on another unique cohort to examine the 
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